[go: up one dir, main page]

WO2015063604A2 - Biomarqueurs prédictifs de la réponse thérapeutique à ifnβ et utilisations de ceux-ci - Google Patents

Biomarqueurs prédictifs de la réponse thérapeutique à ifnβ et utilisations de ceux-ci Download PDF

Info

Publication number
WO2015063604A2
WO2015063604A2 PCT/IB2014/002979 IB2014002979W WO2015063604A2 WO 2015063604 A2 WO2015063604 A2 WO 2015063604A2 IB 2014002979 W IB2014002979 W IB 2014002979W WO 2015063604 A2 WO2015063604 A2 WO 2015063604A2
Authority
WO
WIPO (PCT)
Prior art keywords
mxa
subject
ifn
patients
level
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2014/002979
Other languages
English (en)
Other versions
WO2015063604A3 (fr
Inventor
Luisa IMBERTI
Federico SERANA
Ruggero CAPRA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO2015063604A2 publication Critical patent/WO2015063604A2/fr
Publication of WO2015063604A3 publication Critical patent/WO2015063604A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Definitions

  • MS Multiple sclerosis
  • oligodendrocytes leads to a reduction in the capacity to re-myelinate and may result in the loss of trophic factors that support neurons and axons (Bjartmar et al., (1999) J Neurocytol 28: 383-395).
  • the present invention provides, at least in part, methods, assays and kits for the identification, assessment and/or treatment of a subject having multiple sclerosis (MS).
  • responsiveness of a subject to an interferon beta agent referred to interchangeably herein as an "IFN- ⁇ ,” “IFN-b,” “ ⁇ ,” or “IFNb,” agent
  • IFN- ⁇ la molecule or an IFN- ⁇ lb molecule is predicted by evaluating an alteration (e.g., an increased or decreased level) of an MS biomarker in a sample, e.g., a serum sample obtained from an MS patient.
  • the MS biomarker evaluated is Myxovirus protein-A (MxA), e.g., a change in the level of expression of MxA.
  • MxA Myxovirus protein-A
  • an increase in the level of MxA mRNA is indicative of an improved outcome, e.g., reduced probability of disability progression.
  • the subject is an MS patient who has experienced a relapse (e.g., a severe or mild relapse), also referred to herein as "a subject with relapsing MS.”
  • a relapse e.g., a severe or mild relapse
  • the invention can, therefore, be used, for example: to evaluate responsiveness to, or monitor, a therapy or treatment that includes an IFN-b agent; identify a patient as likely to benefit from a therapy or treatment that includes an IFN-b agent; stratify patient populations (e.g., stratify patients as being likely or unlikely to respond (e.g., responders or disease non-progressors vs.
  • the invention can be used to evaluate the risk of disease progression in a subject with MS who has experienced a relapse (e.g., a severe or mild relapse).
  • the invention features a method of, or assay for, evaluating a sample, e.g., a sample from an MS subject (e.g., a subject with relapsing MS). The method includes detecting an alteration (e.g., an increased or decreased level) of an MS biomarker in the sample.
  • the MS biomarker evaluated includes MxA.
  • the MS biomarker includes an antibody to the IFN-b agent, e.g., a binding antibody (BAb) and/or a neutralizing antibody (NAb).
  • the method, or assay can further include one or more of the following: (i) identifying a subject (e.g., a patient, a patient group or population), having MS (e.g., a subject with relapsing MS), or at risk of developing MS, as having an increased or a decreased likelihood to respond to an MS treatment (or an MS therapy, as used interchangeably herein), e.g. , identifying a subject as a responder or a non-responder to the MS treatment, or as a disease non-progressors vs. disease progressors;
  • identifying a subject e.g., a patient, a patient group or population
  • having MS e.g., a subject with relapsing MS
  • at risk of developing MS as having an increased or a decreased likelihood to respond to an MS treatment (or an MS therapy, as used interchangeably herein)
  • identifying a subject e.g., a responder or a non-responder to the MS treatment, or as
  • determining a treatment regimen upon evaluation of the sample e.g., selecting, or altering the course of, a therapy or treatment, a dose, a treatment schedule or time course, and/or the use of an alternative MS therapy, e.g., altering a therapy from a first-line of MS therapy to a second- line of MS therapy;
  • treating the subject e.g., administering an MS therapy (e.g., a first-line or a second- line MS therapy) to the subject).
  • an MS therapy e.g., a first-line or a second- line MS therapy
  • the MS therapy (e.g., the first-line MS therapy) includes a treatment with an IFN-b agent.
  • the second-line MS therapy is chosen from one or more of: an antibody or fragment thereof against alpha-4 integrin (e.g., natalizumab
  • fingolimod e.g., FTY720; GILENYA®
  • dimethyl fumarate e.g., an oral dimethyl fumarate (TECFIDERA®)
  • an antibody against CD52 e.g., alemtuzumab
  • one or more of (i)-(iv) are determined in response to the detection of the alteration.
  • An alteration e.g., a change, e.g., an increased or a decreased level
  • a specified parameter e.g., a reference value or sample; a sample obtained from a healthy subject; or a sample obtained from the subject at a different time interval, e.g., prior to, during, or after treatment
  • the alteration or change is detected at a single-time point, e.g., prior to an MS therapy; at least one, two, three, four, five, six, seven, eight, nine, ten, eleven, or twelve months after initiation of an MS therapy.
  • the alteration or change is detected at predetermined time intervals, e.g., every 6, 12, 24, 36 or more months after initiation of an MS therapy.
  • an average value of the change or alteration is acquired, e.g., an average value acquired over 6 to 24- month period.
  • an increase in the level in MxA e.g., an increase in the induction of MxA mRNA, in response to an IFN-b agent, in a subject with MS who has experienced a relapse (e.g., a severe or mild relapse) is indicative of an improved outcome, e.g., reduced probability of disability progression.
  • the increase in MxA induced MxA mRNA in response to the IFN-b agent
  • the increase in MxA is indicative of a lower risk of an increase in EDSS score (e.g., a lower risk of a 1 -point EDSS increase).
  • the increase in MxA (induced MxA mRNA in response to the IFN-b agent) is indicative of a reduced probability of disease progression (e.g., a progression similar to a relapse-free patient).
  • either no response or a lower increase in the level of MxA in response to the IFN-b agent is indicative of an increased probability of disability progression in the subject, e.g., a subject with MS who has experienced a relapse (e.g., a severe or mild relapse).
  • the invention features a method of, or assay for, identifying a subject
  • the method includes:
  • a value e.g., obtaining possession of, determining, detecting, or evaluating, the level
  • a subject e.g., a sample from the subject
  • the MS biomarker evaluated includes MxA, and optionally, one or more of: a binding antibody (BAb) or a neutralizing antibody (NAb).
  • BAb binding antibody
  • NAb neutralizing antibody
  • An alteration e.g., a change, e.g., an increased or a decreased level
  • a specified parameter e.g., a reference value or sample; a sample obtained from a healthy subject; or a sample obtained from the subject at a different time interval, e.g., prior to, during, or after treatment
  • an increased or decreased responsiveness of the subject to the IFN-b agent indicates one or more of: an increased or decreased responsiveness of the subject to the IFN-b agent; identifies the subject as having an increased or decreased likelihood to respond to the treatment with the IFN-b agent; or as being a disease progressor or non-progressor.
  • the alteration or change is detected at a single-time point, e.g., prior to an MS therapy; at least one, two, three, four, five, six, seven, eight, nine, ten, eleven, or twelve months after initiation of an MS therapy.
  • the alteration or change is detected at predetermined time intervals, e.g., every 6, 12, 24, 36 or more months after initiation of an MS therapy.
  • an average value of the change or alteration is acquired, e.g., an average value acquired over 6 to 24- month period.
  • an increase in the level in MxA e.g., an increase in the induction of MxA mRNA, in response to an IFN-b agent, in a subject with MS who has experienced a relapse (e.g., a severe or mild relapse) is indicative of an improved outcome, e.g., reduced probability of disability progression.
  • the increase in MxA induced MxA mRNA in response to the IFN-b agent
  • the increase in MxA is indicative of a lower risk of an increase in EDSS score (e.g., a lower risk of a 1 -point EDSS increase).
  • the increase in MxA (induced MxA mRNA in response to the IFN-b agent) is indicative of a reduced probability of disease progression (e.g., a progression similar to a relapse-free patient).
  • either no response or a lower increase in the level of MxA in response to the IFN-b agent is indicative of an increased probability of disability progression in the subject, e.g., a subject with MS who has experienced a relapse (e.g., a severe or mild relap se) .
  • the invention features a method of, or assay for, evaluating or monitoring a treatment (e.g., an MS treatment, e.g. , an MS treatment with an IFN-b agent) in a subject (e.g., a patient, a patient group or population), having MS (e.g., a subject with relapsing MS), or at risk for developing MS.
  • a treatment e.g., an MS treatment, e.g. , an MS treatment with an IFN-b agent
  • the method includes: acquiring a value (e.g., obtaining possession of, determining, detecting, or evaluating, the level) of an MS biomarker in a subject (e.g., a sample from the subject); and
  • the MS biomarker evaluated includes MxA, and optionally, one or more of: a binding antibody (BAb) or a neutralizing antibody (NAb).
  • BAb binding antibody
  • NAb neutralizing antibody
  • the method includes comparing the value of the MS biomarker to a specified parameter (e.g., a reference value or sample; a sample obtained from a healthy subject; or a sample obtained from the subject at a different time interval, e.g., prior to, during, or after treatment).
  • a specified parameter e.g., a reference value or sample; a sample obtained from a healthy subject; or a sample obtained from the subject at a different time interval, e.g., prior to, during, or after treatment.
  • the method can be used, e.g., to evaluate the suitability of, or to choose between alternative treatments, e.g., a particular dosage, mode of delivery, time of delivery, or generally to determine the subject's probable drug response.
  • the invention features a method of, or assay for, evaluating a subject' s prognosis or MS disease progression, in a subject (e.g., a patient, a patient group or population), having MS (e.g., a subject with relapsing MS), or at risk for developing MS.
  • a subject e.g., a patient, a patient group or population
  • MS e.g., a subject with relapsing MS
  • the method includes:
  • acquiring a value e.g., obtaining possession of, determining, detecting, or evaluating, the level
  • a value e.g., obtaining possession of, determining, detecting, or evaluating, the level
  • a subject e.g., a sample from the subject
  • comparing the value of the MS biomarker to a specified parameter e.g., a reference value or sample; a sample obtained from a healthy subject; or a sample obtained from the subject at different time intervals, e.g., prior to, during, or after treatment, e.g. , an MS treatment, e.g. , an MS treatment with an IFN-b agent).
  • a specified parameter e.g., a reference value or sample; a sample obtained from a healthy subject; or a sample obtained from the subject at different time intervals, e.g., prior to, during, or after treatment, e.g. , an MS treatment, e.g. , an MS treatment with an IFN-b agent.
  • the MS biomarker evaluated includes MxA, and optionally, one or more of: a binding antibody (BAb) or a neutralizing antibody (NAb).
  • BAb binding antibody
  • NAb neutralizing antibody
  • an alteration e.g., a change, e.g., an increased or a decreased level
  • an alteration or change indicates one or more of: an increased or decreased responsiveness of the subject to the IFN-b agent; identifies the subject as having an increased or decreased likelihood to respond to the treatment with the IFN-b agent; or as being a disease progressor or non-progressor.
  • the alteration or change is detected at a single-time point, e.g., prior to an MS therapy; at least one, two, three, four, five, six, seven, eight, nine, ten, eleven, or twelve months after initiation of an MS therapy.
  • the alteration or change is detected at predetermined time intervals, e.g., every 6, 12, 24, 36 or more months after initiation of an MS therapy.
  • an average value of the change or alteration is acquired, e.g., an average value acquired over 6 to 24- month period.
  • an increase in the level in MxA e.g., an increase in the induction of MxA mRNA, in response to an IFN-b agent, in a subject with MS who has experienced a relapse (e.g., a severe or mild relapse) is indicative of an improved outcome, e.g., reduced probability of disability progression.
  • the increase in MxA induced MxA mRNA in response to the IFN-b agent
  • the increase in MxA is indicative of a lower risk of an increase in EDSS score (e.g., a lower risk of a 1 -point EDSS increase).
  • the increase in MxA (induced MxA mRNA in response to the IFN-b agent) is indicative of a reduced probability of disease progression (e.g., a progression similar to a relapse-free patient).
  • either no response or a lower increase in the level of MxA in response to the IFN-b agent is indicative of an increased probability of disability progression in the subject, e.g., a subject with MS who has experienced a relapse (e.g., a severe or mild relap se) .
  • any of the aforesaid methods further include treating, or preventing in, a subject having MS one or more symptoms associated with MS.
  • the treatment includes reducing, retarding or preventing, a relapse, or the progression of a disability, in the MS subject.
  • the method includes, responsive to an MS biomarker value (e.g., an MS biomarker value obtained as described herein), administering to the subject (e.g. , a patient with relap sing-remitting multiple sclerosis (RRMS)) a therapy for MS (also referred to herein as an "MS therapy”), e.g. , an MS therapy with an IFN-b agent, in an amount sufficient to reduce one or more symptoms associated with MS.
  • an MS biomarker value e.g., an MS biomarker value obtained as described herein
  • administering e.g. , a patient with relap sing-remitting multiple sclerosis (RRMS)
  • a therapy for MS also referred to herein as an "MS
  • the invention features a method of treating, or preventing in, MS (e.g., one or more symptoms associated with MS), in a subject having MS (e.g., a subject with MS who has experienced a relapse (e.g., a severe or mild relapse)), or at risk for developing MS.
  • MS e.g., one or more symptoms associated with MS
  • a subject having MS e.g., a subject with MS who has experienced a relapse (e.g., a severe or mild relapse)
  • the subject is identified as having an increased or decreased probability of showing disability progression, using the methods, or assays, described herein.
  • the method includes:
  • a value (e.g., obtaining possession of, determining, detecting, or evaluating the level) of an MS biomarker chosen from MxA, and optionally, one or more of: a binding antibody (BAb) or a neutralizing antibody (NAb), in a subject;
  • BAb binding antibody
  • NAb neutralizing antibody
  • a therapy for MS e.g., an MS therapy with an IFN-b agent, in an amount sufficient to reduce one or more symptoms associated with MS.
  • the method of treatment includes an MS therapy (e.g., a first-line MS therapy), e.g. , an MS therapy that includes an ⁇ agent (e.g., an IFN- ⁇ l a molecule or an IFN- ⁇ lb molecule, including analogues and derivatives thereof (e.g., pegylated variants thereof)).
  • the MS therapy includes an IFN- ⁇ la agent (e.g., AVONEX®, REBIF®).
  • the MS therapy includes an INF- ⁇ lb agent (e.g.,
  • the MS therapy is an alternative therapy (e.g., a therapy selected when a patient is non-responsive to an INF- ⁇ therapy).
  • the MS therapy is an alternative therapy to the IFN- ⁇ agent, e.g., a second-line MS therapy.
  • the second-line MS therapy is chosen from one or more of: an antibody or fragment thereof against alpha-4 integrin (e.g., natalizumab
  • TLSABRI® a fingolimod
  • FTY720 a fingolimod
  • GILENYA® a S IP-agonist
  • TECFIDERA® an oral dimethyl fumarate
  • LEMTRADA® alemtuzumab
  • the alternative therapy to the IFN- ⁇ agent includes a polymer of four amino acids found in myelin basic protein, e.g., a polymer of glutamic acid, lysine, alanine and tyrosine (e.g., glatiramer (COPAXONE®)).
  • the alternative therapy includes an antibody or fragment thereof against alpha-4 integrin (e.g., natalizumab (TYSABRI®).
  • the alternative therapy includes an anthracenedione molecule (e.g., mitoxantrone (NOVANTRONE®)).
  • the alternative therapy includes a fingolimod (e.g., FTY720; GILENYA®).
  • the alternative therapy is a dimethyl fumarate (e.g., an oral dimethyl fumarate (TECFIDERA®)).
  • the alternative therapy is an antibody to the alpha subunit of the IL-2 receptor of T cells (e.g., Daclizumab).
  • the alternative therapy is an antibody against CD52 (e.g., alemtuzumab (LEMTRADA®)).
  • the method further includes the use of one or more symptom management therapies, such as antidepressants, analgesics, anti-tremor agents, among others.
  • symptom management therapies such as antidepressants, analgesics, anti-tremor agents, among others.
  • the subject treated, or the subject from which the sample is obtained is a subject having, or at risk of having MS at any stage of treatment.
  • the subject has experienced one or more relapses (e.g., mild or severe relapses).
  • the subject has a negative status for an interferon antibody or a neutralizing antibody.
  • the subject is NAb-BAb-.
  • the subject has a positive status for an interferon antibody or a neutralizing antibody, or both (e.g., NAb+BAb-; NAb-BAb+, or NAb+BAb+).
  • the MS patient is chosen from a patient having one or more of: Benign MS, RRMS (e.g., quiescent RRMS, active RRMS), primary progressive MS, or secondary progressive MS.
  • the subject has MS-like symptoms, such as those having clinically isolated syndrome (CIS) or clinically defined MS (CDMS).
  • the subject is an MS patient (e.g. , a patient with RRMS) after administration of an MS therapy described herein (e.g., after administration of an IFN-b agent).
  • the subject has a relapsing form of MS (e.g., RRMS or relapsing SPMS).
  • the subject has RRMS and has one or more ongoing clinical exacerbations and/or subclinical activity, e.g., as shown by gadolinium (Gd) enhancement or development of new and/or enlarged T2/FLAIR lesions on magnetic resonance imaging (e.g., brain or spinal cord MRI).
  • Gd gadolinium
  • the subject has SPMS and has one or more ongoing clinical exacerbations and/or subclinical activity, e.g., as shown by gadolinium (Gd) enhancement or development of new and/or enlarged T2/FLAIR lesions on magnetic resonance imaging (e.g., brain or spinal cord MRI).
  • Gd gadolinium
  • the subject has an active form of MS, e.g., an active RRMS.
  • the MS subject has at least one newly developed lesion.
  • the MS subject has at least one pre-existing lesion.
  • the subject has RRMS, and has one or more newly developed or pre-existing lesions, or a combination thereof.
  • the subject has a baseline EDSS score of 1.5 to 7.
  • the subject is an MS patient after administration of the MS therapy for one, two weeks, one month, two months, three months, four months, six months, one year or more.
  • the alteration or change is detected at a single-time point, e.g., prior to an MS therapy; at least one, two, three, four, five, six, seven, eight, nine, ten, eleven, or twelve months after initiation of an MS therapy.
  • the alteration or change is detected at predetermined time intervals, e.g, every 6, 12, 24, 36 or more months after initiation of an MS therapy.
  • an average value of the change or alteration is acquired, e.g., an average value acquired over 6 to 24- month period.
  • the MxA level can be evaluated at one or more intervals post-injection of the IFN-b agent. In one embodiment, the MxA level is evaluated 9 to 15 hours, or 10- 12 hours, after injection of the IFN-b agent, e.g., post-injection of IFN- ⁇ 1 agent chosen from AVONEX®, REBIF®, BETASERON®, or BETAFERON®. In other embodiments, the MxA level is evaluated 10 to 60 hours, or 12 to 48 hours post-injection of a pegylated form of the IFN- ⁇ 1 agent.
  • the method or assay includes comparing the value (e.g., level) of one or more MS biomarkers to a specified parameter (e.g., a reference value or sample; a sample obtained from a healthy subject; a sample obtained from a patient at different treatment intervals).
  • a sample can be analyzed at any stage of treatment, but preferably, prior to, during, or after terminating, administration of the MS therapy, to thereby determine appropriate dosage(s) and treatment regimen(s) of the MS therapy (e.g., amount per treatment or frequency of treatments) for prophylactic or therapeutic treatment of the subject.
  • the methods, or assays, of the invention include the step of detecting the level of one or more MS biomarkers in the subject, prior to, or after, administering the MS therapy, to the subject.
  • an increase in the level in MxA e.g., an increase in the induction of MxA mRNA, in response to an IFN-b agent, in a subject with MS who has experienced a relapse (e.g., a severe or mild relapse) is indicative of an improved outcome, e.g., reduced probability of disability progression.
  • the increase in MxA induced MxA mRNA in response to the IFN-b agent
  • the increase in MxA is indicative of a lower risk of an increase in EDSS score (e.g., a lower risk of a 1 -point EDSS increase).
  • the increase in MxA (induced MxA mRNA in response to the IFN-b agent) is indicative of a reduced probability of disease progression (e.g., a progression similar to a relapse-free patient).
  • either no response or a lower increase in the level of MxA in response to the IFN-b agent is indicative of an increased probability of disability progression in the subject, e.g., a subject with MS who has experienced a relapse (e.g., a severe or mild relapse).
  • the method, or assay further includes the step of obtaining the sample, e.g., a biological sample, from the subject.
  • the method, or assay includes the step of obtaining a predominantly non-cellular fraction of a body fluid from the subject.
  • the non-cellular fraction can be plasma, serum, or other non-cellular body fluid.
  • the sample is a serum sample.
  • the detection or determining steps of the methods or assays described herein include determining quantitatively the value (e.g., level) (e.g., amount or concentration) of an MS biomarker (e.g., one or more of the MS biomarkers described herein) from a sample, e.g., a sample of plasma, serum, or other non-cellular body fluid, wherein the amount or concentration of the MS biomarker, thereby provides a value (also referred to herein as a "determined,” or “detected,” “value”).
  • level e.g., amount or concentration
  • an MS biomarker e.g., one or more of the MS biomarkers described herein
  • the determined or detected value is compared to a specified parameter (e.g., a reference value; a control sample; a sample obtained from a healthy subject; a sample obtained from the subject at different time intervals, e.g., prior to, during, or after treatment, or a pre-determined value).
  • a specified parameter e.g., a reference value; a control sample; a sample obtained from a healthy subject; a sample obtained from the subject at different time intervals, e.g., prior to, during, or after treatment, or a pre-determined value.
  • the sample is assayed for qualitative, or both quantitative and qualitative determination of the MS biomarker level.
  • methods or assays of the invention relate to determining quantitatively the amount or concentration of the MS biomarker from plasma or serum of the subject, wherein the plasma or serum is obtained from the blood of the subject, for example.
  • the MS biomarker evaluated is a gene or gene product, e.g., cDNA, RNA (e.g., mRNA), or a polypeptide.
  • the MS biomarker is a nucleic acid
  • the nucleic acid can be detected, or the level determined, by any means of nucleic acid detection, or detection of the expression level of the nucleic acids, including but not limited to, nucleic acid hybridization assay, amplification-based assays (e.g., polymerase chain reaction), or sequencing.
  • the MS biomarker is evaluated using a real-time PCR assay.
  • the one or more MS biomarkers are assessed at predetermined intervals, e.g., a first point in time and at least at a subsequent point in time.
  • a time course is measured by determining the time between significant events in the course of a patient's disease, wherein the measurement is predictive of whether a patient has a long time course.
  • the significant event is the progression from primary diagnosis to death.
  • the significant event is the progression from primary diagnosis to disease progression.
  • the significant event is the progression from primary diagnosis to relapse.
  • the significant event is the progression from secondary MS to death.
  • the significant event is the progression from remission to relapse.
  • the significant event is the progression from relapse to death.
  • the time course is measured with respect to one or more overall survival rate, time to progression and/or using the EDSS or other assessment criteria.
  • the method or assays disclosed herein can further include one or more steps of:
  • EDSS Expanded Disability Status Scale
  • the methods, assays, and/or kits described herein further include providing or generating, and/or transmitting information, e.g. , a report, containing data of the evaluation or treatment determined by the methods, assays, and/or kits as described herein.
  • the information can be transmitted to a report-receiving party or entity (e.g., a patient, a health care provider, a diagnostic provider, and/or a regulatory agency, e.g., the FDA), or otherwise submitting information about the methods, assays and kits disclosed herein to another party.
  • the method can relate to compliance with a regulatory requirement, e.g., a pre- or post approval requirement of a regulatory agency, e.g., the FDA.
  • the report-receiving party or entity can determine if a predetermined requirement or reference value is met by the data, and, optionally, a response from the report-receiving entity or party is received, e.g., by a physician, patient, diagnostic provider.
  • kits for evaluating a sample e.g., a sample from an MS patient, to detect or determine the level of one or more MS biomarkers.
  • Figure 1A is a schematic depicting exemplary longitudinal analysis of participation of patients treated with IFNP, including exemplary times and/or reasons for exclusion from the study. Patients' disposition and dropouts during the 3-year study period are shown. Reported as adverse events are the following (comprising both drug-related and drug-independent clinical events): injection site reaction (1), thyroiditis (1), liver enzyme elevation (4), leucopenia (1), kidney stones (1), migraine (1), pregnancy (1), breast nodule (1), and breast cancer (1).
  • Figure IB is a table showing dropout distribution, a: see Figure 1A for more details, b: early dropouts were excluded from the analysis because only one post-therapy MxA
  • T12, T24, T36 12, 24, 36 months post-therapy initiation.
  • Figure 1C is a table showing baseline characteristics of the 100 patients analyzed.
  • FIGS 2A-2C depict exemplary levels of MxA (relative units, Figure 2A), BAb (% activity, Figure 2B) and NAb (titer, Figure 2C) in patients treated with IFNP over a 36 month time period.
  • MxA values Figure 2A) in patients treated with IFNP-la i.m. (clear circles, dashed grey line), IFNP-la s.c. (clear squares, solid grey line), IFNP-lb s.c. (clear diamonds, solid black line).
  • MxA myxovirus-resistance protein A
  • NR normalization ratio
  • BAbs binding antibodies
  • NAbs neutralizing antibodies
  • ⁇ interferon beta
  • Figure 3 depicts exemplary BAb levels (% total activity) at TO in patients that were naive for therapy with IFNP as compared to healthy donors.
  • BAb binding antibodies.
  • Figure 4 depicts exemplary levels of log BAb and MxA (relative units) in patients treated with ⁇ -la i.m., ⁇ -la s.c. 44 ⁇ g, or ⁇ -lb s.c. MxA and anti- ⁇ antibodies in all samples of all patients.
  • the lines indicate the cut-offs.
  • MxA myxovirus-resistance protein A
  • NR normalization ratio
  • BAbs binding antibodies
  • NAbs neutralizing antibodies.
  • Figures 5A-5B depict exemplary quantitation of mRNA expression of IFNAR2.2 over time in patients treated with ⁇ -la i.m., ⁇ -la s.c. 44 ⁇ g, or ⁇ -lb (Figure 5A); and an exemplary multivariate regression model performed after correcting for the presence of anti- ⁇ antibodies and type of ⁇ received, to show average MxA mRNA levels ( Figure 5B).
  • Average decrease of IFNAR2.2 mRNA ( Figure 5A) in patients treated with ⁇ -la i.m. (clear circles, dashed grey line), ⁇ -la s.c. (clear squares, solid grey line), ⁇ -lb s.c. (clear diamonds, solid black line).
  • IFNAR interferon receptor
  • IFNP interferon beta
  • MxA myxovirus-resistance protein A
  • NR normalization ratio
  • Figure 5C is a table showing exemplary characteristics of the patients and classification according to IFNP-bioactivity profiles.
  • IFNP interferon beta
  • MxA myxovirus-resistence protein A
  • BAb binding antibodies
  • NAb neutralizing antibodies.
  • Figure 5D is a table showing exemplary markers of disease activity/progression in the patients with the different IFNP-bioactivity profiles, a: excluding the group of patients with intermediate features; BAb: binding antibodies; Abs: antibodies; ARR: annualized replapse rate; AEDSS: variation in Expanded Disability Status Scale.
  • Figures 6A-6C depict exemplary effects of MxA on the probability of EDSS increase at various timepoints.
  • Figure 6A depicts an exemplary comparison of MxA values obtained across multiple observations in patients with or without disability progression.
  • Figure 6B depicts exemplary area under the curve (AUC) analysis for MxA in patients at T24 months in patients with a change in EDSS score of less than one or an EDSS score of greater than one.
  • Figure 6C depicts exemplary risk of change in EDSS score at T24 months in patients as a function of MxA (relative units) in patients without relapses in 24 months or in patients with at least one relapse in 24 months.
  • Figure 7 is a table showing an exemplary logistic model for EDSS increase.
  • Figures 8A depicts exemplary analysis of IFNP-bioactive patients who were MxA+
  • Figure 8B depicts exemplary analysis of patients who displayed sporadic (non-consecutive) MxA- samples without antibodies and were considered bona fide bioactive patients.
  • Figure 8C depicts exemplary analysis of IFNP-treated patients who were BAb+ at several timepoints, but had conserved MxA induction.
  • Figure 8D depicts
  • Figure 9 depicts exemplary analysis of the effect of IFNAR2.3 on MxA.
  • Figure 10 depicts exemplary analysis of the effect of MxA on the probability of 24- month EDSS increase.
  • MS multiple sclerosis
  • responsiveness of a subject to an interferon beta ("IFN- ⁇ " or "IFN-b") agent is determined by evaluating an alteration (e.g., an increased or decreased level) of an MS biomarker in a sample, e.g., a serum sample obtained from an MS patient.
  • an alteration e.g., an increased or decreased level
  • the MS biomarker evaluated is MxA.
  • the articles “a” and “an” refer to one or to more than one (e.g., to at least one) of the grammatical object of the article.
  • “About” and “approximately” shall generally mean an acceptable degree of error for the quantity measured given the nature or precision of the measurements. Exemplary degrees of error are within 20 percent (%), typically, within 10%, and more typically, within 5% of a given value or range of values.
  • Acquire or “acquiring” as the terms are used herein, refer to obtaining possession of a physical entity (e.g., a sample, a polypeptide, a nucleic acid, or a sequence), or a value, e.g., a numerical value, by “directly acquiring” or “indirectly acquiring” the physical entity or value.
  • Directly acquiring means performing a process (e.g., performing a synthetic or analytical method) to obtain the physical entity or value.
  • Indirectly acquiring refers to receiving the physical entity or value from another party or source (e.g., a third party laboratory that directly acquired the physical entity or value).
  • Directly acquiring a physical entity includes performing a process that includes a physical change in a physical substance, e.g., a starting material.
  • exemplary changes include making a physical entity from two or more starting materials, shearing or fragmenting a substance, separating or purifying a substance, combining two or more separate entities into a mixture, performing a chemical reaction that includes breaking or forming a covalent or non-covalent bond.
  • Directly acquiring a value includes performing a process that includes a physical change in a sample or another substance, e.g., performing an analytical process which includes a physical change in a substance, e.g., a sample, analyte, or reagent (sometimes referred to herein as "physical analysis"), performing an analytical method, e.g., a method which includes one or more of the following:
  • separating or purifying a substance e.g., an analyte, or a fragment or other derivative thereof, from another substance; combining an analyte, or fragment or other derivative thereof, with another substance, e.g., a buffer, solvent, or reactant; or changing the structure of an analyte, or a fragment or other derivative thereof, e.g., by breaking or forming a covalent or non-covalent bond, between a first and a second atom of the analyte; or by changing the structure of a reagent, or a fragment or other derivative thereof, e.g., by breaking or forming a covalent or non-covalent bond, between a first and a second atom of the reagent.
  • altered level of expression of a biomarker as described herein refers to an increase (or decrease) in the expression level of a marker in a test sample, such as a sample derived from a patient suffering from multiple sclerosis or a similar disorder (e.g., clinically isolated syndrome (CIS), benign MS), that is greater or less than the standard error of the assay employed to assess expression.
  • a test sample such as a sample derived from a patient suffering from multiple sclerosis or a similar disorder (e.g., clinically isolated syndrome (CIS), benign MS), that is greater or less than the standard error of the assay employed to assess expression.
  • CIS clinically isolated syndrome
  • the alteration can be at least twice, at least twice three, at least twice four, at least twice five, or at least twice ten or more times greater than or less than the expression level of the biomarkers in a control sample (e.g., a sample from a healthy subject not having the associated disease), or the average expression level in several control samples.
  • a control sample e.g., a sample from a healthy subject not having the associated disease
  • An "altered level of expression” can be determined at the protein or nucleic acid (e.g., mRNA) level.
  • Binding compound shall refer to a binding composition, such as a small molecule, an antibody, a peptide, a peptide or non-peptide ligand, a protein, an oligonucleotide, an oligonucleotide analog, such as a peptide nucleic acid, a lectin, or any other molecular entity that is capable of specifically binding to a target protein or molecule or stable complex formation with an analyte of interest, such as a complex of proteins.
  • Binding moiety means any molecule to which molecular tags can be directly or indirectly attached that is capable of specifically binding to an analyte. Binding moieties include, but are not limited to, antibodies, antibody binding compositions, peptides, proteins, nucleic acids and organic molecules having a molecular weight of up to about 1000 daltons and containing atoms selected from the group consisting of hydrogen, carbon, oxygen, nitrogen, sulfur and phosphorus.
  • a “biomarker” or “marker” is a gene, mRNA, or protein that undergoes alterations in expression that are associated with multiple sclerosis or responsiveness to treatment with IFN- ⁇ .
  • the alteration can be in amount and/or activity in a biological sample (e.g., a blood, plasma, or a serum sample) obtained from a subject having multiple sclerosis, as compared to its amount and/or activity, in a biological sample obtained from a healthy subject (e.g., a control); such alterations in expression and/or activity are associated with a disease state, such as multiple sclerosis.
  • a marker of the invention which is associated with multiple sclerosis or predictive of responsiveness to IFN- ⁇ therapeutics can have an altered expression level, protein level, or protein activity, in a biological sample obtained from a subject having, or suspected of having, multiple sclerosis as compared to a biological sample obtained from a control subject (e.g., a healthy individual).
  • a “nucleic acid” “marker” or “biomarker” is a nucleic acid (e.g. , DNA, mRNA, cDNA) encoded by or corresponding to a marker as described herein.
  • marker nucleic acid molecules include DNA (e.g. , genomic DNA and cDNA) comprising the entire or a partial sequence of any of the nucleic acid sequences set forth herein (e.g., in Table 1), or the complement or hybridizing fragment of such a sequence.
  • the marker nucleic acid molecules also include RNA comprising the entire or a partial sequence of any of the nucleic acid sequences set forth herein, or the complement of such a sequence, wherein all thymidine residues are replaced with uridine residues.
  • a “marker protein” is a protein encoded by or corresponding to a marker of the invention.
  • a marker protein comprises the entire or a partial sequence of a protein encoded by any of the sequences set forth herein, or a fragment thereof.
  • the terms “protein” and “polypeptide” are used interchangeably herein.
  • a marker is "fixed" to a substrate if it is covalently or non-covalently associated with the substrate such that the substrate can be rinsed with a fluid (e.g., standard saline citrate, pH 7.4) without a substantial fraction of the marker dissociating from the substrate.
  • a fluid e.g., standard saline citrate, pH 7.4
  • sequence similarity refers to sequence similarity between two polynucleotide sequences or between two polypeptide sequences, with identity being a more strict comparison.
  • percent identity or homology and “% identity or homology” refer to the percentage of sequence similarity found in a comparison of two or more polynucleotide sequences or two or more polypeptide sequences.
  • sequence similarity refers to the percent similarity in base pair sequence (as determined by any suitable method) between two or more polynucleotide sequences. Two or more sequences can be anywhere from 0-100% similar, or any integer value there between.
  • Identity or similarity can be determined by comparing a position in each sequence that can be aligned for purposes of comparison. When a position in the compared sequence is occupied by the same nucleotide base or amino acid, then the molecules are identical at that position.
  • a degree of similarity or identity between polynucleotide sequences is a function of the number of identical or matching nucleotides at positions shared by the polynucleotide sequences.
  • a degree of identity of polypeptide sequences is a function of the number of identical amino acids at positions shared by the polypeptide sequences.
  • a degree of homology or similarity of polypeptide sequences is a function of the number of amino acids at positions shared by the polypeptide sequences.
  • the term "substantial homology,” as used herein, refers to homology of at least 50%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or more.
  • Multiple sclerosis is “treated,” “inhibited” or “reduced,” if at least one symptom of the disease is reduced, alleviated, terminated, slowed, or prevented. As used herein, multiple sclerosis is also “treated,” “inhibited,” or “reduced,” if recurrence or relapse of the disease is reduced, slowed, delayed, or prevented.
  • Exemplary clinical symptoms of multiple sclerosis that can be used to aid in determining the disease status in a subject can include e.g., tingling, numbness, muscle weakness, loss of balance, blurred or double vision, slurred speech, sudden onset paralysis, lack of coordination, cognitive difficulties, fatigue, heat sensitivity, spasticity, dizziness, tremors, gait abnormalities, speech/swallowing difficulties, and extent of lesions assessed by imaging techniques, e.g., MRI.
  • Clinical symptoms of MS are routinely classified and standardized, e.g., using an EDSS rating system. Typically, a decrease of one full step indicates an effective MS treatment (Kurtzke, Ann. Neurol. 36:573-79, 1994), while an increase of one full step will indicate the progression or worsening of the disease (e.g., exacerbation).
  • therapy e.g., MS therapy or MS treatment
  • treatment e.g., MS therapy or MS treatment
  • EDSS Extended Disability Status Scale
  • EDSS is a rating system that is frequently used for classifying and standardizing MS.
  • the accepted scores range from 0 (normal) to 10 (death due to MS).
  • patients having an EDSS score of about 6 will have moderate disability (e.g., walk with a cane), whereas patients having an EDSS score of about 7 or 8 will have severe disability (e.g., will require a wheelchair).
  • EDSS scores in the range of 1-3 refer to an MS patient who is fully ambulatory, but has some signs in one or more functional systems; EDSS scores in the range higher than 3 to 4.5 show moderate to relatively severe disability; an EDSS score of 5 to 5.5 refers to a disability imparing or precluding full daily activities; EDSS scores of 6 to 6.5 refer to an MS patient requiring intermittent to constant, or unilateral to bilateral constant assistance (cane, crutch or brace) to walk; EDSS scores of 7 to 7.5 means that the MS patient is unable to walk beyond five meters even with aid, and is essentially restricted to a wheelchair; EDSS scores of 8 to 8.5 refer to patients that are restricted to bed; and EDSS scores of 9 to 10 mean that the MS patient is confined to bed, and progressively is unable to communicate effectively or eat and swallow, until death due to MS.
  • an “overexpression” or “significantly higher level of expression” of the gene products refers to an expression level or copy number in a test sample that is greater than the standard error of the assay employed to assess the level of expression.
  • overexpression can be at least two, at least three, at least four, at least five, or at least ten or more times the expression level of the gene products in a control sample (e.g., a sample from a healthy subject not afflicted with multiple sclerosis), or the average expression level of gene products in several control samples.
  • a control sample e.g., a sample from a healthy subject not afflicted with multiple sclerosis
  • probe refers to any molecule which is capable of selectively binding to a specifically intended target molecule, for example a marker of the invention. Probes can be either synthesized by one skilled in the art, or derived from appropriate biological preparations. For purposes of detection of the target molecule, probes can be specifically designed to be labeled, as described herein. Examples of molecules that can be utilized as probes include, but are not limited to, RNA, DNA, proteins, antibodies, and organic monomers.
  • Responsiveness to “respond” to treatment, and other forms of this verb, as used herein, refer to the reaction of a subject to treatment with an MS therapy, e.g., a therapy including an IFN- ⁇ agent.
  • an MS therapy e.g., a therapy including an IFN- ⁇ agent.
  • a subject responds to treatment with an IFN- ⁇ agent if at least one symptom of multiple sclerosis (e.g., relapse rate) in the subject is reduced or retarded by about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more.
  • a subject responds to treatment with an IFN- ⁇ agent, if at least one symptom of multiple sclerosis in the subject is reduced by about 5%, 10%, 20%, 30%, 40%, 50% or more as determined by any appropriate measure, e.g., Expanded Disability Status Scale (EDSS) or determining the extent of other symptoms such as relapse rate, muscle weakness, tingling, and numbness.
  • EDSS Expanded Disability Status Scale
  • a subject responds to treatment with an IFN- ⁇ agent, if the subject experiences a life expectancy extended by about 5%, 10%, 20%, 30%, 40%, 50% or more beyond the life expectancy predicted if no treatment is administered.
  • a subject responds to treatment with an IFN- ⁇ agent, if the subject has an increased disease-free survival, overall survival or increased time to progression.
  • IFN- ⁇ agent Several methods can be used to determine if a patient responds to a treatment including the EDSS criteria, as set forth above.
  • a “responder” refers to a subject, e.g., an MS patient, if in response to an MS therapy (e.g., IFN beta therapy), at least one symptom of multiple sclerosis in the subject is reduced by about 5%, 10%, 20%, 30%, 40%, 50% or more as determined by any appropriate measure, e.g., EDSS or determining the extent of other symptoms such as relapse rate, muscle weakness, tingling, and numbness.
  • a responder is defined as a subject with no confirmed relapses and no evidence of sustained disability progression (by EDSS) during the first three years of treatment (e.g., clinical remission).
  • a “non-responder” refers to a subject, e.g., an MS patient, if in response to an MS therapy (e.g., IFN beta therapy), at least one symptom of multiple sclerosis in the subject is reduced by less than about 5%, as determined by any appropriate measure, e.g., EDSS or determining the extent of other symptoms such as relapse rate, muscle weakness, tingling, and numbness.
  • a non-responder is defined as those subjects that have active disease on therapy including subjects with at least 3 relapses, development of a 6-month sustained progression in disability defined as a 1.0 point increase in EDSS score from baseline in subjects with a baseline score of ⁇ 5.5. Subjects were excluded for having > 10 MRI T2 lesions in the remission or permanently testing positive for NAB starting from year 1 at any titer or NAB titers > 20 in either group.
  • “Likely to” or “increased likelihood,” as used herein, refers to an increased probability that an item, object, thing or person will occur.
  • a subject that is likely to respond to treatment with an IFN- ⁇ agent to treat multiple sclerosis has an increased probability of responding to treatment with an IFN- ⁇ agent to treat multiple sclerosis, relative to a reference subject or group of subjects.
  • Unlikely to refers to a decreased probability that an event, item, object, thing or person will occur with respect to a reference.
  • a subject that is unlikely to respond to treatment with an IFN- ⁇ agent has a decreased probability of responding to treatment with an IFN- ⁇ agent relative to a reference subject or group of subjects.
  • tissue sample each refers to a biological sample obtained from a tissue or bodily fluid of a subject or patient.
  • the source of the tissue sample can be solid tissue as from a fresh, frozen and/or preserved organ, tissue sample, biopsy, or aspirate; blood or any blood constituents (e.g., serum, plasma); bodily fluids such as cerebral spinal fluid, whole blood, plasma and serum.
  • the sample can include a non-cellular fraction (e.g., plasma, serum, or other non-cellular body fluid).
  • the sample is a serum sample.
  • the body fluid from which the sample is obtained from an individual comprises blood (e.g., whole blood).
  • the blood can be further processed to obtain plasma or serum.
  • the sample contains a tissue, cells (e.g., peripheral blood mononuclear cells (PBMC)).
  • PBMC peripheral blood mononuclear cells
  • the sample can be a fine needle biopsy sample, an archival sample (e.g., an archived sample with a known diagnosis and/or treatment history), a histological section (e.g., a frozen or formalin-fixed section, e.g., after long term storage), among others.
  • PBMC peripheral blood mononuclear cells
  • the term sample includes any material obtained and/or derived from a biological sample, including a polypeptide, and nucleic acid (e.g., genomic DNA, cDNA, RNA) purified or processed from the sample. Purification and/or processing of the sample can involve one or more of extraction,
  • the sample can contain compounds that are not naturally intermixed with the tissue in nature such as preservatives, anticoagulants, buffers, fixatives, nutrients, antibiotics or the like.
  • the amount of a biomarker e.g., expression of gene products (e.g. , one or more the biomarkers described herein), in a subject is "significantly" higher or lower than the normal amount of a marker, if the amount of the marker is greater or less, respectively, than the normal level by an amount greater than the standard error of the assay employed to assess amount, or at least two, three, four, five, ten or more times that amount.
  • the amount of the marker in the subject can be considered "significantly" higher or lower than the normal amount if the amount is at least about 1.5, two, at least about three, at least about four, or at least about five times, higher or lower, respectively, than the normal amount of the marker.
  • significant event shall refer to an event in a patient's disease that is important as determined by one skilled in the art.
  • significant events include, for example, without limitation, primary diagnosis, death, recurrence, remission, relapse of a patient's disease or the progression of a patient's disease from any one of the above noted stages to another.
  • a significant event can be any important event used determine disease status using e.g., EDSS or other symptom criteria, as determined by one skilled in the art.
  • time course shall refer to the amount of time between an initial event and a subsequent event.
  • time course can relate to a patient's disease and can be measured by gauging significant events in the course of the disease, wherein the first event can be diagnosis and the subsequent event can be remission or relapse, for example.
  • a “transcribed polynucleotide” is a polynucleotide (e.g., an RNA, a cDNA, or an analog of one of an RNA or cDNA) which is complementary to or homologous with all or a portion of a mature RNA made by transcription of a marker of the invention and normal post-transcriptional processing (e.g., splicing), if any, of the transcript, and reverse transcription of the transcript.
  • normal post-transcriptional processing e.g., splicing
  • an “underexpression” or “significantly lower level of expression” of products refers to an expression level in a test sample that is greater than the standard error of the assay employed to assess expression, for example, at least 1.5, twice, at least three, at least four, at least five, or at least ten or more times less than the expression level of the gene products in a control sample (e.g. , a sample from a healthy subject not afflicted with multiple sclerosis), or the average expression level of gene products in several control samples.
  • MS Multiple sclerosis
  • Patients having MS can be identified by clinical criteria establishing a diagnosis of clinically definite MS as defined by Poser et al., Ann. Neurol. 13:227, 1983. Briefly, an individual with clinically definite MS has had two attacks and clinical evidence of either two lesions or clinical evidence of one lesion and paraclinical evidence of another, separate lesion. Definite MS may also be diagnosed by evidence of two attacks and oligoclonal bands of IgG in cerebrospinal fluid or by combination of an attack, clinical evidence of two lesions and oligoclonal band of IgG in cerebrospinal fluid. The McDonald criteria can also be used to diagnose MS.
  • the McDonald criteria include the use of MRI evidence of CNS impairment over time to be used in diagnosis of MS, in the absence of multiple clinical attacks. Effective treatment of multiple sclerosis may be evaluated in several different ways. The following parameters can be used to gauge effectiveness of treatment. Two exemplary criteria include: EDSS (extended disability status scale), and appearance of exacerbations on MRI (magnetic resonance imaging).
  • the EDSS is a means to grade clinical impairment due to MS (Kurtzke, Neurology
  • Exacerbations are defined as the appearance of a new symptom that is attributable to MS and accompanied by an appropriate new neurologic abnormality (IFNB MS Study Group, supra). In addition, the exacerbation must last at least 24 hours and be preceded by stability or improvement for at least 30 days. Briefly, patients are given a standard neurological examination by clinicians. Exacerbations are mild, moderate, or severe according to changes in a
  • Treatment can be deemed to be effective using a clinical measure if there is a statistically significant difference in the rate or proportion of exacerbation-free or relapse-free patients between the treated group and the placebo group for either of these measurements.
  • time to first exacerbation and exacerbation duration and severity may also be measured.
  • a measure of effectiveness as therapy in this regard is a statistically significant difference in the time to first exacerbation or duration and severity in the treated group compared to control group.
  • An exacerbation-free or relapse-free period of greater than one year, 18 months, or 20 months is particularly noteworthy.
  • Clinical measurements include the relapse rate in one and two-year intervals, and a change in EDSS, including time to progression from baseline of 1.0 unit on the EDSS that persists for six months. On a Kaplan-Meier curve, a delay in sustained progression of disability shows efficacy. Other criteria include a change in area and volume of T2 images on MRI, and the number and volume of lesions determined by gadolinium enhanced images.
  • MRI can be used to measure active lesions using gadolinium-DTPA-enhanced imaging (McDonald et al., Ann. Neurol. 36: 14, 1994) or the location and extent of lesions using T2- weighted techniques. Briefly, baseline MRIs are obtained. The same imaging plane and patient position are used for each subsequent study. Positioning and imaging sequences can be chosen to maximize lesion detection and facilitate lesion tracing. The same positioning and imaging sequences can be used on subsequent studies. The presence, location and extent of MS lesions can be determined by radiologists. Areas of lesions can be outlined and summed slice by slice for total lesion area. Three analyses may be done: evidence of new lesions, rate of appearance of active lesions, percentage change in lesion area (Paty et al., Neurology 43:665, 1993).
  • Improvement due to therapy can be established by a statistically significant improvement in an individual patient compared to baseline or in a treated group versus a placebo group.
  • Exemplary symptoms associated with multiple sclerosis which can be treated with the methods described herein or managed using symptom management therapies, include: optic neuritis, diplopia, nystagmus, ocular dysmetria, internuclear opthalmoplegia, movement and sound phosphenes, afferent pupillary defect, paresis, monoparesis, paraparesis, hemiparesis, quadraparesis, plegia, paraplegia, hemiplegia, tetraplegia, quadraplegia, spasticity, dysarthria, muscle atrophy, spasms, cramps, hypotonia, clonus, myoclonus, myokymia, restless leg syndrome, footdrop, dysfunctional reflexes, paraesthesia, anaesthesia, neuralgia, neuropathic and neurogenic pain, l'hermitte's, proprioceptive dysfunction, trigeminal neuralgia, ataxia, intention tre
  • MS relap sing-remitting MS
  • PPMS Primary-progressive MS
  • SPMS Secondary-progressive MS
  • PRMS progressive-relapsing
  • malignant MS defined as a swift and relentless decline resulting in significant disability or even death shortly after disease onset. This decline may be arrested or decelerated by determining the likelihood of the patient to respond to a therapy early in the therapeutic regime and switching the patient to an agent that they have the highest likelihood of responding to.
  • MxA as a biomarker, which correlates with the efficacy of IFN- ⁇ agents, alone or in combination, e.g., in combination with another agent for treating multiple sclerosis, in a subject.
  • the present invention provides methods for evaluation of expression level, protein level, protein activity of e.g., MxA.
  • methods of the present invention can be used to determine the responsiveness of a subject to treatment with an IFN- ⁇ agent (e.g., an ⁇ - ⁇ , an ⁇ - ⁇ , or a derivative thereof (e.g., a PEGylated derivative)), wherein if a sample in a subject has a significant increase in the amount, e.g., expression, and/or activity of a marker disclosed herein relative to a standard, e.g., the level of expression and/or activity in a healthy subject then the disease is more likely to respond to treatment with an the IFN- ⁇ agent, alone or in combination with other therapies for multiple sclerosis, and vice versa.
  • an IFN- ⁇ agent e.g., an ⁇ - ⁇ , an ⁇ - ⁇ , or a derivative thereof (e.g., a PEGylated derivative)
  • MxA Myxovirus protein- A
  • the nucleotide and protein sequences of human MxA are described, e.g., Aebi et al. (1989) Mol. Cell. Biol. 9:5062-5072; Horisberger et al. (1990) J.
  • MxA can be obtained from e.g., SIGMA-ALDRICH®, ORIGENETM, ABNOVATM, and SANTA CRUZ BIOTECHNOLOGY®.
  • ⁇ treatment e.g. ⁇ - ⁇ , ⁇ - ⁇ , or a derivative thereof (e.g., a pegylated derivative)
  • initiation of such treatment e.g., pre-therapy
  • expression of MxA measured in a subject at least 2 weeks, at least 1 month, at least 3 months, at least 6 months, or at least 1 year after initiation of therapy.
  • it is preferred that expression of MxA is measured less than 6 months after initiation of therapy to permit the skilled practitioner to switch the subject to a different therapeutic strategy.
  • expression of MxA is measured within 1-6 months, 1-5 months, 1-4 months, 1-3 months, 1-2 months, 2-6 months, 3- 6 months, 4-6 months, 5-6 months, 2-3 months, 3-4 months, or 4-5 months of initiation of ⁇ therapy.
  • the expression of MxA is determined 3-6 months after initiation of therapy (e.g., 3 months, 3.5 months, 4 months, 4.5 months, 5 months, 5.5 months, 6 months).
  • the methods described herein can also be used to monitor a positive response of a subject to treatment with ⁇ . Such methods are useful for early detection of tolerance to ⁇ therapy or to predict whether a subject will shift from a responder to a non-responder phenotype.
  • the level (e.g., expression) of MxA is determined e.g., at least every week, at least every 2 weeks, at least every month, at least every 2 months, at least every 3 months, at least every 4 months, at least every 5 months, at least every 6 months, at least every 7 months, at least every 8 months, at least every 9 months, at least every 10 months, at least every 11 months, at least every year, at least every 18 months, at least every 2 years, at least every 3 years, at least every 5 years or more.
  • expression of the biomarkers is at irregular intervals e.g., biomarkers can be detected in an individual at 3 months of treatment, at 6 months of treatment, and at 7 months of treatment.
  • the expression of the biomarkers is determined when deemed necessary by the skilled physician monitoring treatment of the subject.
  • CIS clinically isolated syndrome
  • CDMS clinically defined MS
  • a subject that is identified as a responder using the methods described herein can be treated with any ⁇ agent known in the art presently or to be developed (e.g. ⁇ - ⁇ , ⁇ - 1B, or a derivative thereof (e.g., a pegylated derivative)).
  • the ⁇ agent is an ⁇ - lA agent (e.g., AVONPX®, RPBIF®).
  • the ⁇ agent is an ⁇ -lB agent (e.g., BPTASPRON®, BPTAFPRON®).
  • the amount of the biomarker determined in a serum sample from a subject is quantified as an absolute measurement (e.g., ng/mL).
  • Absolute measurements can easily be compared to a reference value or cut-off value.
  • a cut-off value can be determined that represents a non-responder status; any absolute values falling either above (i.e., for biomarkers that increase expression with MS) or falling below (i.e., for biomarkers with decreased expression in MS) the cut-off value are likely to be non-responders to ⁇ therapy.
  • the relative amount of a biomarker is determined.
  • the relative amount is determined by comparing the expression of one or more serum biomarkers in a subject with MS to the expression of the serum biomarkers in a healthy control subject.
  • the relative amount is determined by comparing the expression of MxA in a subject with MS at two or more timepoints (e.g., at baseline and monthly beginning 6 months after initiation of therapy).
  • the present invention also pertains to the field of predictive medicine in which diagnostic assays, pharmacogenomics, and monitoring clinical trials are used for predictive purposes to thereby treat an individual prophylactically. Accordingly, one aspect of the present invention relates to assays for determining the amount, structure, and/or activity of polypeptides or nucleic acids corresponding to one or more markers of the invention, in order to determine whether an individual having multiple sclerosis or at risk of developing multiple sclerosis will be more likely to respond to IFN ⁇ -mediated therapy.
  • the invention is drawn to a method for determining whether a subject with multiple sclerosis is likely to respond to treatment with an IFN- ⁇ agent.
  • the invention is drawn to a method for predicting a time course of disease.
  • the method is drawn to a method for predicting a probability of a significant event in the time course of the disease (e.g., relapse or shift from responder to non-responder status).
  • the method comprises detecting a biomarker or combination of biomarkers associated with responsiveness to treatment with an IFN- ⁇ agent as described herein and determining whether the subject is likely to respond to treatment with the IFN- ⁇ agent
  • the methods involve evaluation of a biological sample e.g., a serum sample from a subject, e.g., a patient who has been diagnosed with or is suspected of having multiple sclerosis (e.g. , presents with symptoms of multiple sclerosis) to detect changes in MxA (e.g., gene expression or polypeptide levels).
  • a biological sample e.g., a serum sample from a subject, e.g., a patient who has been diagnosed with or is suspected of having multiple sclerosis (e.g. , presents with symptoms of multiple sclerosis) to detect changes in MxA (e.g., gene expression or polypeptide levels).
  • results of the screening method and the interpretation thereof are predictive of the patient's response to treatment with IFN- ⁇ agents (e.g. , AVONEX®, REBIF®, BETASERON®, BETAFERON®), alone or in combination with symptom management agents.
  • IFN- ⁇ agents e.g. , AVONEX®, REBIF®, BETASERON®, BETAFERON®
  • alterations in expression of MxA is indicative that treatment with IFN- ⁇ agents will provide enhanced therapeutic benefit for patients with multiple sclerosis relative to healthy controls.
  • the one or more alterations, e.g., alterations in biomarker expression are assessed at pre-determined intervals, e.g., a first point in time and at least at a subsequent point in time.
  • a time course is measured by determining the time between significant events in the course of a patient's disease, wherein the measurement is predictive of whether a patient has a long time course.
  • the significant event is the progression from primary diagnosis to death.
  • the significant event is the progression from primary diagnosis to worsening disease.
  • the significant event is the progression from primary diagnosis to relapse.
  • the significant event is the progression from secondary MS to death. In another embodiment, the significant event is the progression from remission to relapse. In another embodiment, the significant event is the progression from relapse to death. In certain
  • the time course is measured with respect to one or more overall survival rate, time to progression and/or using the EDSS or other assessment criteria.
  • Marker expression level can also be assayed.
  • Expression of a marker of the invention can be assessed by any of a wide variety of well known methods for detecting expression of a transcribed molecule or protein. Non-limiting examples of such methods include immunological methods for detection of secreted, cell-surface, cytoplasmic, or nuclear proteins, protein purification methods, protein function or activity assays, nucleic acid hybridization methods, nucleic acid reverse transcription methods, and nucleic acid amplification methods.
  • activity of a particular gene is characterized by a measure of gene transcript (e.g., mRNA), by a measure of the quantity of translated protein, or by a measure of gene product activity.
  • Marker expression can be monitored in a variety of ways, including by detecting mRNA levels, protein levels, or protein activity, any of which can be measured using standard techniques. Detection can involve quantification of the level of gene expression (e.g., genomic DNA, cDNA, mRNA, protein, or enzyme activity), or, alternatively, can be a qualitative assessment of the level of gene expression, in particular in comparison with a control level. The type of level being detected will be clear from the context.
  • mRNA or cDNA made therefrom Methods of detecting and/or quantifying the gene transcript (mRNA or cDNA made therefrom) using nucleic acid hybridization techniques are known to those of skill in the art (see e.g., Sambrook et al. supra).
  • one method for evaluating the presence, absence, or quantity of cDNA involves a Southern transfer as described above. Briefly, the mRNA is isolated ⁇ e.g., using an acid guanidinium-phenol-chloroform extraction method, Sambrook et al. supra.) and reverse transcribed to produce cDNA. The cDNA is then optionally digested and run on a gel in buffer and transferred to membranes. Hybridization is then carried out using the nucleic acid probes specific for the target cDNA.
  • a general principle of such diagnostic and prognostic assays involves preparing a sample or reaction mixture that can contain a marker, and a probe, under appropriate conditions and for a time sufficient to allow the marker and probe to interact and bind, thus forming a complex that can be removed and/or detected in the reaction mixture.
  • These assays can be conducted in a variety of ways.
  • one method to conduct such an assay would involve anchoring the marker or probe onto a solid phase support, also referred to as a substrate, and detecting target marker/probe complexes anchored on the solid phase at the end of the reaction.
  • a sample from a subject which is to be assayed for presence and/or concentration of marker, can be anchored onto a carrier or solid phase support.
  • the reverse situation is possible, in which the probe can be anchored to a solid phase and a sample from a subject can be allowed to react as an unanchored component of the assay.
  • the non-immobilized component is added to the solid phase upon which the second component is anchored.
  • uncomplexed components can be removed ⁇ e.g. , by washing) under conditions such that any complexes formed will remain immobilized upon the solid phase.
  • the detection of marker/probe complexes anchored to the solid phase can be accomplished in a number of methods outlined herein.
  • the probe when it is the unanchored assay component, can be labeled for the purpose of detection and readout of the assay, either directly or indirectly, with detectable labels discussed herein and which are well-known to one skilled in the art. It is also possible to directly detect marker/probe complex formation without further manipulation or labeling of either component (marker or probe), for example by utilizing the technique of fluorescence energy transfer (see, for example, Lakowicz et al., U.S. Patent No. 5,631,169; Stavrianopoulos, et al., U.S. Patent No. 4,868,103).
  • a fluorophore label on the first, 'donor' molecule is selected such that, upon excitation with incident light of appropriate wavelength, its emitted fluorescent energy will be absorbed by a fluorescent label on a second 'acceptor' molecule, which in turn is able to fluoresce due to the absorbed energy.
  • the 'donor' protein molecule can simply utilize the natural fluorescent energy of tryptophan residues. Labels are chosen that emit different wavelengths of light, such that the 'acceptor' molecule label can be differentiated from that of the 'donor' . Since the efficiency of energy transfer between the labels is related to the distance separating the molecules, spatial
  • determination of the ability of a probe to recognize a marker can be accomplished without labeling either assay component (probe or marker) by utilizing a technology such as real-time Biomolecular Interaction Analysis (BIA) (see, e.g., Sjolander, S. and Urbaniczky, C, 1991, Anal. Chem. 63:2338-2345 and Szabo et al., 1995, Curr. Opin. Struct. Biol. 5:699-705).
  • BIOA Biomolecular Interaction Analysis
  • surface plasmon resonance is a technology for studying biospecific interactions in real time, without labeling any of the interactants ⁇ e.g., BIAcore).
  • analogous diagnostic and prognostic assays can be conducted with marker and probe as solutes in a liquid phase.
  • the complexed marker and probe are separated from uncomplexed components by any of a number of standard techniques, including but not limited to: differential centrifugation, chromatography,
  • marker/probe complexes can be separated from uncomplexed assay components through a series of centrifugal steps, due to the different sedimentation equilibria of complexes based on their different sizes and densities (see, for example, Rivas, G., and Minton, A.P., 1993, Trends Biochem Sci. 18(8):284-7).
  • Standard chromatographic techniques can also be utilized to separate complexed molecules from uncomplexed ones.
  • gel filtration chromatography separates molecules based on size, and through the utilization of an appropriate gel filtration resin in a column format, for example, the relatively larger complex can be separated from the relatively smaller uncomplexed components.
  • the relatively different charge properties of the marker/probe complex as compared to the uncomplexed components can be exploited to differentiate the complex from uncomplexed components, for example, through the utilization of ion-exchange chromatography resins.
  • Such resins and chromatographic techniques are well known to one skilled in the art (see, e.g., Heegaard, N.H., 1998, J. Mol. Recognit.
  • Gel electrophoresis can also be employed to separate complexed assay components from unbound components (see, e.g., Ausubel et ah, ed., Current Protocols in Molecular Biology, John Wiley & Sons, New York, 1987-1999). In this technique, protein or nucleic acid complexes are separated based on size or charge, for example. In order to maintain the binding interaction during the electrophoretic process, non-denaturing gel matrix materials and conditions in the absence of reducing agent are typical. Appropriate conditions to the particular assay and components thereof will be well known to one skilled in the art.
  • the level of mRNA corresponding to the marker can be determined both by in situ and by in vitro formats in a biological sample using methods known in the art.
  • biological sample is intended to include tissues, cells, biological fluids and isolates thereof, isolated from a subject, as well as tissues, cells and fluids present within a subject.
  • Many expression detection methods use isolated RNA.
  • any RNA isolation technique that does not select against the isolation of mRNA can be utilized for the purification of RNA from cells (see, e.g., Ausubel et ah, ed., Current Protocols in Molecular Biology, John Wiley & Sons, New York 1987-1999).
  • the isolated nucleic acid can be used in hybridization or amplification assays that include, but are not limited to, Southern or Northern analyses, polymerase chain reaction analyses and probe arrays.
  • One diagnostic method for the detection of mRNA levels involves contacting the isolated mRNA with a nucleic acid molecule (probe) that can hybridize to the mRNA encoded by the gene being detected.
  • the nucleic acid probe can be, for example, a full- length cDNA, or a portion thereof, such as an oligonucleotide of at least 7, 15, 30, 50, 100, 250 or 500 nucleotides in length and sufficient to specifically hybridize under stringent conditions to a mRNA or genomic DNA encoding a marker of the present invention.
  • oligonucleotide of at least 7, 15, 30, 50, 100, 250 or 500 nucleotides in length and sufficient to specifically hybridize under stringent conditions to a mRNA or genomic DNA encoding a marker of the present invention.
  • Other suitable probes for use in the diagnostic assays of the invention are described herein. Hybridization of an mRNA with the probe indicates that the marker in question is being expressed.
  • the mRNA is immobilized on a solid surface and contacted with a probe, for example by running the isolated mRNA on an agarose gel and transferring the mRNA from the gel to a membrane, such as nitrocellulose.
  • the probe(s) are immobilized on a solid surface and the mRNA is contacted with the probe(s), for example, in an Affymetrix gene chip array.
  • a skilled artisan can readily adapt known mRNA detection methods for use in detecting the level of mRNA encoded by the markers of the present invention.
  • the probes can be full length or less than the full length of the nucleic acid sequence encoding the protein. Shorter probes are empirically tested for specificity. Exemplary nucleic acid probes are 20 bases or longer in length (See, e.g., Sambrook et al. for methods of selecting nucleic acid probe sequences for use in nucleic acid hybridization). Visualization of the hybridized portions allows the qualitative determination of the presence or absence of cDNA.
  • An alternative method for determining the level of a transcript corresponding to a marker of the present invention in a sample involves the process of nucleic acid amplification, e.g., by rtPCR (the experimental embodiment set forth in Mullis, 1987, U.S. Patent No. 4,683,202), ligase chain reaction (Barany, 1991, Proc. Natl. Acad. Sci. USA, 88: 189-193), self sustained sequence replication (Guatelli et al, 1990, Proc. Natl. Acad. Sci. USA 87: 1874-1878), transcriptional amplification system (Kwoh et al., 1989, Proc. Natl. Acad. Sci.
  • Fluorogenic rtPCR can also be used in the methods of the invention. In fluorogenic rtPCR, quantitation is based on amount of fluorescence signals, e.g., TaqMan and sybr green. These detection schemes are especially useful for the detection of nucleic acid molecules if such molecules are present in very low numbers.
  • amplification primers are defined as being a pair of nucleic acid molecules that can anneal to 5' or 3' regions of a gene (plus and minus strands, respectively, or vice-versa) and contain a short region in between.
  • amplification primers are from about 10 to 30 nucleotides in length and flank a region from about 50 to 200 nucleotides in length. Under appropriate conditions and with appropriate reagents, such primers permit the amplification of a nucleic acid molecule comprising the nucleotide sequence flanked by the primers.
  • mRNA does not need to be isolated from the cells prior to detection.
  • a cell or tissue sample is prepared/processed using known histological methods.
  • the sample is then immobilized on a support, typically a glass slide, and then contacted with a probe that can hybridize to mRNA that encodes the marker.
  • determinations can be based on the normalized expression level of the marker.
  • Expression levels are normalized by correcting the absolute expression level of a marker by comparing its expression to the expression of a gene that is not a marker, e.g., a housekeeping gene that is constitutively expressed.
  • Suitable genes for normalization include housekeeping genes such as the actin gene, or epithelial cell-specific genes. This normalization allows the comparison of the expression level in one sample, e.g., a subject sample, to another sample, e.g., a healthy subject, or between samples from different sources.
  • the expression level can be provided as a relative expression level.
  • the level of expression of the marker is determined for 10 or more samples of normal versus MS isolates, or even 50 or more samples, prior to the determination of the expression level for the sample in question.
  • the mean expression level of each of the genes assayed in the larger number of samples is determined and this is used as a baseline expression level for the marker.
  • the expression level of the marker determined for the test sample (absolute level of expression) is then divided by the mean expression value obtained for that marker. This provides a relative expression level.
  • the samples used in the baseline determination will be from samples derived from a subject having multiple sclerosis versus samples from a healthy subject of the same tissue type.
  • the choice of the cell source is dependent on the use of the relative expression level. Using expression found in normal tissues as a mean expression score aids in validating whether the marker assayed is specific to the tissue from which the cell was derived (versus normal cells).
  • the mean expression value can be revised, providing improved relative expression values based on accumulated data.
  • Expression data from normal cells provides a means for grading the severity of the multiple sclerosis disease state.
  • expression of a marker is assessed by preparing genomic DNA or mRNA/cDNA (i.e., a transcribed polynucleotide) from cells in a subject sample, and by hybridizing the genomic DNA or mRNA/cDNA with a reference polynucleotide which is a complement of a polynucleotide comprising the marker, and fragments thereof.
  • cDNA can, optionally, be amplified using any of a variety of polymerase chain reaction methods prior to hybridization with the reference polynucleotide.
  • Expression of one or more markers can likewise be detected using quantitative PCR (QPCR) to assess the level of expression of the marker(s).
  • any of the many known methods of detecting mutations or variants (e.g., single nucleotide polymorphisms, deletions, etc.) of a marker of the invention can be used to detect occurrence of a mutated marker in a subject.
  • a mixture of transcribed polynucleotides obtained from the sample is contacted with a substrate having fixed thereto a polynucleotide complementary to or homologous with at least a portion (e.g., at least 7, at least 10, at least 15, at least 20, at least 25, at least 30, at least 40, at least 50, at least 100, at least 500, or more nucleotide residues) of a marker of the invention.
  • a portion e.g., at least 7, at least 10, at least 15, at least 20, at least 25, at least 30, at least 40, at least 50, at least 100, at least 500, or more nucleotide residues
  • polynucleotides complementary to or homologous with a marker of the invention are differentially detectable on the substrate (e.g., detectable using different chromophores or fluorophores, or fixed to different selected positions), then the levels of expression of a plurality of markers can be assessed simultaneously using a single substrate (e.g., a "gene chip" microarray of polynucleotides fixed at selected positions).
  • a method of assessing marker expression which involves hybridization of one nucleic acid with another, the hybridization can be performed under stringent hybridization conditions.
  • compositions, kits, and methods of the invention rely on detection of a difference in expression levels of one or more markers of the invention, in certain embodiments the level of expression of the marker is significantly greater than the minimum detection limit of the method used to assess expression in at least one of a biological sample from a subject with MS or a healthy control.
  • One aspect of the invention pertains to isolated nucleic acid molecules that correspond to one or markers of the invention, including nucleic acids which encode a polypeptide
  • nucleic acid molecules of the invention include those nucleic acid molecules which reside in genomic regions identified herein. Isolated nucleic acid molecules of the invention also include nucleic acid molecules sufficient for use as hybridization probes to identify nucleic acid molecules that correspond to a marker of the invention, including nucleic acid molecules which encode a polypeptide corresponding to a marker of the invention, and fragments of such nucleic acid molecules, e.g., those suitable for use as PCR primers for the amplification or mutation of nucleic acid molecules.
  • nucleic acid molecule is intended to include DNA molecules ⁇ e.g., cDNA or genomic DNA) and RNA molecules ⁇ e.g., mRNA) and analogs of the DNA or RNA generated using nucleotide analogs.
  • the nucleic acid molecule can be single- stranded or double-stranded; in certain embodiments the nucleic acid molecule is double- stranded DNA.
  • an “isolated” nucleic acid molecule is one which is separated from other nucleic acid molecules which are present in the natural source of the nucleic acid molecule.
  • an “isolated” nucleic acid molecule is free of sequences (such as protein-encoding sequences) which naturally flank the nucleic acid ⁇ i.e., sequences located at the 5' and 3' ends of the nucleic acid) in the genomic DNA of the organism from which the nucleic acid is derived.
  • nucleic acid molecule that is substantially free of cellular material includes preparations of nucleic acid molecule having less than about 30%, less than about 20%, less than about 10%, or less than about 5% (by dry weight) of other cellular material or culture medium.
  • nucleic acid molecule of the present invention e.g., the marker gene products identified herein
  • a nucleic acid molecule of the present invention can be isolated using standard molecular biology techniques and the sequence information in the database records described herein. Using all or a portion of such nucleic acid sequences, nucleic acid molecules of the invention can be isolated using standard hybridization and cloning techniques (e.g., as described in Sambrook et al., ed., Molecular Cloning: A Laboratory Manual, 2nd ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989).
  • a nucleic acid molecule of the invention can be amplified using cDNA, mRNA, or genomic DNA as a template and appropriate oligonucleotide primers according to standard PCR amplification techniques.
  • the nucleic acid molecules so amplified can be cloned into an appropriate vector and characterized by DNA sequence analysis.
  • oligonucleotides corresponding to all or a portion of a nucleic acid molecule of the invention can be prepared by standard synthetic techniques, e.g., using an automated DNA synthesizer.
  • Probes based on the sequence of a nucleic acid molecule of the invention can be used to detect transcripts (e.g., mRNA) or genomic sequences corresponding to one or more markers of the invention.
  • the probe comprises a label group attached thereto, e.g., a radioisotope, a fluorescent compound, an enzyme, or an enzyme co-factor.
  • Such probes can be used as part of a diagnostic test kit for identifying cells or tissues which mis-express the protein, such as by measuring levels of a nucleic acid molecule encoding the protein in a sample of cells from a subject, e.g., detecting mRNA levels or determining whether a gene encoding the protein has been mutated or deleted.
  • Methods to measure biomarkers of this invention include, but are not limited to: Western blot, immunoblot, enzyme-linked immunosorbant assay (ELISA), radioimmunoassay (RIA), immunoprecipitation, surface plasmon resonance, chemiluminescence, fluorescent polarization, phosphorescence, immunohistochemical analysis, liquid chromatography mass spectrometry (LC-MS), matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry, microcytometry, microarray, microscopy, fluorescence activated cell sorting (FACS), flow cytometry, laser scanning cytometry, hematology analyzer and assays based on a property of the protein including but not limited to DNA binding, ligand binding, or interaction with other protein partners.
  • ELISA enzyme-linked immunosorbant assay
  • RIA radioimmunoassay
  • immunoprecipitation surface plasmon resonance
  • chemiluminescence chemilum
  • the activity or level of a marker protein can also be detected and/or quantified by detecting or quantifying the expressed polypeptide.
  • the polypeptide can be detected and quantified by any of a number of means well known to those of skill in the art. These can include analytic biochemical methods such as electrophoresis, capillary electrophoresis, high
  • HPLC performance liquid chromatography
  • TLC thin layer chromatography
  • hyperdiffusion chromatography and the like
  • immunological methods such as fluid or gel precipitin reactions, immunodiffusion (single or double), Immunoelectrophoresis, radioimmunoassay (RIA), enzyme-linked immunosorbent assays (ELISAs), immunofluorescent assays, Western blotting, immunohistochemistry and the like.
  • RIA radioimmunoassay
  • ELISAs enzyme-linked immunosorbent assays
  • immunofluorescent assays Western blotting
  • immunohistochemistry and the like.
  • a skilled artisan can readily adapt known protein/antibody detection methods for use in determining the expression level of one or more biomarkers in a serum sample.
  • Another agent for detecting a polypeptide of the invention is an antibody capable of binding to a polypeptide corresponding to a marker of the invention, e.g., an antibody with a detectable label.
  • Antibodies can be polyclonal or monoclonal. An intact antibody, or a fragment thereof (e.g. , Fab or F(ab') 2 ) can be used.
  • the term "labeled", with regard to the probe or antibody is intended to encompass direct labeling of the probe or antibody by coupling (i.e. , physically linking) a detectable substance to the probe or antibody, as well as indirect labeling of the probe or antibody by reactivity with another reagent that is directly labeled. Examples of indirect labeling include detection of a primary antibody using a fluorescently labeled secondary antibody and end-labeling of a DNA probe with biotin such that it can be detected with fluorescently labeled streptavidin.
  • the antibody is labeled, e.g., a radio-labeled, chromophore- labeled, fluorophore-labeled, or enzyme-labeled antibody.
  • an antibody derivative e.g., an antibody conjugated with a substrate or with the protein or ligand of a protein-ligand pair ⁇ e.g., biotin-streptavidin ⁇
  • an antibody fragment e.g., a single-chain antibody, an isolated antibody hypervariable domain, etc.
  • Proteins from cells can be isolated using techniques that are well known to those of skill in the art.
  • the protein isolation methods employed can, for example, be such as those described in Harlow and Lane (Harlow and Lane, 1988, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York).
  • antibodies, or antibody fragments can be used in methods such as Western blots or immunofluorescence techniques to detect the expressed proteins.
  • Suitable solid phase supports or carriers include any support capable of binding an antigen or an antibody.
  • Well-known supports or carriers include glass, polystyrene, polypropylene, polyethylene, dextran, nylon, amylases, natural and modified celluloses, polyacrylamides, gabbros, and magnetite.
  • the polypeptide is detected using an immunoassay.
  • an immunoassay is an assay that utilizes an antibody to specifically bind to the analyte. The immunoassay is thus characterized by detection of specific binding of a polypeptide to an anti-antibody as opposed to the use of other physical or chemical properties to isolate, target, and quantify the analyte.
  • the polypeptide is detected and/or quantified using any of a number of well recognized immunological binding assays (see, e.g., U.S. Patent Nos. 4,366,241; 4,376,110; 4,517,288; and 4,837,168).
  • immunological binding assays see, e.g., U.S. Patent Nos. 4,366,241; 4,376,110; 4,517,288; and 4,837,168.
  • the polypeptide is detected and/or quantified using LuminexTM assay technology.
  • the LUMINEXTM assay separates tiny color-coded beads into e.g., distinct sets that are each coated with a reagent for a particular bioassay, allowing the capture and detection of specific analytes from a sample in a multiplex manner.
  • the LUMINEXTM assay technology can be compared to a multiplex ELISA assay using bead-based fluorescence cytometry to detect analytes such as biomarkers.
  • kits for detecting the presence of a polypeptide or nucleic acid corresponding to a marker of the invention in a biological sample e.g., a sample containing tissue, whole blood, serum, plasma, buccal scrape, saliva, cerebrospinal fluid, urine, stool, and bone marrow.
  • a biological sample e.g., a sample containing tissue, whole blood, serum, plasma, buccal scrape, saliva, cerebrospinal fluid, urine, stool, and bone marrow.
  • the kit can comprise a labeled compound or agent capable of detecting a polypeptide or an mRNA encoding a polypeptide corresponding to a marker of the invention in a biological sample and means for determining the amount of the polypeptide or mRNA in the sample (e.g. , an antibody which binds the
  • polypeptide or an oligonucleotide probe which binds to DNA or mRNA encoding the
  • Kits can also include instructions for interpreting the results obtained using the kit.
  • the invention thus includes a kit for assessing the responsiveness of a subject having multiple sclerosis to treatment using an IFN- ⁇ agent (e.g., in a sample such as a serum sample).
  • Suitable reagents for binding with a polypeptide corresponding to a marker of the invention include antibodies, antibody derivatives, antibody fragments, and the like.
  • Suitable reagents for binding with a nucleic acid include complementary nucleic acids.
  • the nucleic acid reagents can include oligonucleotides (labeled or non-labeled) fixed to a substrate, labeled oligonucleotides not bound with a substrate, pairs of PCR primers, molecular beacon probes, and the like.
  • the kit of the invention can optionally comprise additional components useful for performing the methods of the invention.
  • the kit can comprise fluids (e.g., SSC buffer) suitable for annealing complementary nucleic acids or for binding an antibody with a protein with which it specifically binds, one or more sample compartments, an instructional material which describes performance of a method of the invention, a reference sample for comparison of expression levels of the biomarkers described herein, and the like.
  • kits of the invention can comprise a reagent useful for determining protein level or protein activity of a marker.
  • Beta interferons e.g., AVONEX®
  • Interferons are natural proteins produced by the cells of the immune systems of most animals in response to challenges by foreign agents such as viruses, bacteria, parasites and tumor cells. Interferons belong to the large class of glycoproteins known as cytokines. Interferon beta has 165 amino acids. Interferons alpha and beta are produced by many cell types, including T-cells and B-cells, macrophages, fibroblasts, endothelial cells, osteoblasts and others, and stimulate both
  • Interferon gamma is involved in the regulation of immune and inflammatory responses. It is produced by activated T-cells and Thl cells.
  • Interferon alpha (including forms interferon alpha-2a, interferon alpha- 2b, and interferon alfacon-1) was approved by the United States Food and Drug Administration (FDA) as a treatment for Hepatitis C.
  • FDA United States Food and Drug Administration
  • Interferon beta la is FDA-approved type of interferon beta.
  • interferon beta (AVONEX®) is identical to interferon beta found naturally in humans, and interferon beta lb (BETASERON®) differs in certain ways from interferon beta la found naturally in humans, including that it contains a serine residue in place of a cysteine residue at position 17.
  • Other uses of interferon beta have included treatment of AIDS, cutaneous T-cell lymphoma, Acute Hepatitis C (non-A, non-B), Kaposi's sarcoma, malignant melanoma, and metastatic renal cell carcinoma.
  • IFN- ⁇ agents can be administered to the subject by any method known in the art, including systemically ⁇ e.g., orally, parenterally, subcutaneously, intravenously, rectally, intramuscularly, intraperitoneally, intranasally, transdermally, or by inhalation or intracavitary installation). Typically, the IFN- ⁇ agents are administered subcutaneously, or intramuscularly.
  • IFN- ⁇ agents can be used to treat those subjects determined to be "responders" using the methods described herein.
  • the IFN- ⁇ agents are used as a monotherapy although the treatment regimen can further comprise the use of "symptom management therapies" such as antidepressants, analgesics, anti-tremor agents, etc.
  • the IFN- ⁇ agent is an ⁇ -lA agent (e.g., AVONEX®, REBIF®).
  • the INF- ⁇ agent is an ⁇ -lB agent (e.g., BETASERON®, BETAFERON®).
  • AVONEX® an Interferon ⁇ -la
  • AVONEX® is indicated for the treatment of patients with relapsing forms of MS that are determined to be responders using the methods described herein to slow the accumulation of physical disability and decrease the frequency of clinical exacerbations.
  • AVONEX® Interferon beta- la
  • AVONEX® is a 166 amino acid glycoprotein with a predicted molecular weight of approximately 22,500 daltons. It is produced by recombinant DNA technology using genetically engineered Chinese Hamster Ovary cells into which the human interferon beta gene has been introduced.
  • the amino acid sequence of AVONEX® is identical to that of natural human interferon beta.
  • the recommended dosage of AVONEX® (Interferon beta- la) is 30 meg injected intramuscularly once a week.
  • AVONEX® is commercially available as a 30 meg lyophilized powder vial or as a 30 meg prefilled syringe.
  • Interferon beta la (AVONEX®) is identical to interferon beta found naturally in humans (AVONEX®, i.e., Interferon beta la (SwissProt Accession No. P01574 and gi:50593016).
  • the sequence of interferon beta is:
  • the IFN-b agent includes an amino acid sequence substantially identical to SEQ ID NO: l, e.g., at least 70%, 80%, 90% or 95% identical to SEQ ID NO: l.
  • compositions e.g., IFN beta la molecules
  • Such other compositions include, e.g., other interferons and fragments, analogues, homologues, derivatives, and natural variants thereof with substantially similar biological activity.
  • the INF- ⁇ agent is modified to increase one or more pharmacokinetic properties.
  • the INF- ⁇ agent can be a modified form of interferon la to include a pegylated moiety. PEGylated forms of interferon beta la are described in, e.g., Baker, D.P. et al.
  • Pegylated forms of IFN beta la can be administered by, e.g., injectable routes of administration (e.g., subcutaneously).
  • REBIF® is also an Interferon ⁇ -la agent, while BETASERON® and BETAFERON® are Interferon ⁇ lb agents. Both REBIF® and BETASERON® are formulated for administration by subcutaneous injection.
  • IFN- ⁇ agents to administer can be determined by one of skill in the art, and include clinically acceptable amounts to administer based on the specific interferon-beta agent used.
  • AVONEX® is typically administered at 30 microgram once a week via intramuscular injection.
  • Other forms of interferon beta la, specifically REBIF®, is administered, for example, at 22 microgram three times a week or 44 micrograms once a week, via
  • Interferon beta- 1A can be administered, e.g., intramuscularly, in an amount of between 10 and 50 ⁇ g.
  • AVONEX® can be administered every five to ten days, e.g., once a week, while REBIF® can be administered three times a week.
  • Non-IFN- ⁇ agents e.g., AVONEX® can be administered every five to ten days, e.g., once a week, while REBIF® can be administered three times a week.
  • alternative therapies to the IFN- ⁇ agent can be administered.
  • a skilled physician can select a therapy that includes a non-IFN- ⁇ agent that can include, e.g., glatiramer (COPAXONE®), natalizumab (TYSABRI®, ANTEGREN®), and mitoxantrone (NOVANTRONE®).
  • Anti-VLA4 antibody e.g., Natalizumab (TYSABRI®)
  • TLSABRI® Natalizumab
  • Anti-VLA4 antibodies inhibit the migration of leukocytes from the blood to the central nervous system. These antibodies bind to VLA-4 (also called ⁇ 4 ⁇ 1) on the surface of activated T-cells and other mononuclear leukocytes. They can disrupt adhesion between the T-cell and endothelial cells, and thus prevent migration of mononuclear leukocytes across the endothelium and into the parenchyma. As a result, the levels of pro-inflammatory cytokines can also be reduced.
  • VLA-4 also called ⁇ 4 ⁇ 1
  • Natalizumab can decrease the number of brain lesions and clinical relapses and accumulation of disability in patients with relapse remitting multiple sclerosis and relapsing secondary-progressive multiple sclerosis.
  • Natalizumab and related VLA-4 binding antibodies are described, e.g., in U.S. Pat. No. 5,840,299.
  • Monoclonal antibodies 21.6 and HP1/2 are exemplary murine monoclonal antibodies that bind VLA-4.
  • Natalizumab is a humanized version of murine monoclonal antibody 21.6 (see, e.g., U.S. Pat. No. 5,840,299).
  • a humanized version of HP 1/2 has also been described (see, e.g., U.S. Pat. No. 6,602,503).
  • VLA-4 binding monoclonal antibodies such as
  • HP2/1, HP2/4, L25 and P4C2 are described, e.g., in U.S. Pat. No. 6,602,503; Sanchez-Madrid et al, (1986) Eur. J. Immunol 16: 1343-1349; Hemler et al, (1987) J Biol. Chem. 2: 11478-11485; Issekutz et al. (1991) J Immunol 147: 109 (TA-2 mab); Pulido et al. (1991) J Biol. Chem. 266: 10241-10245; and U.S. Pat. No. 5,888,507).
  • the contents of the aforesaid publications are described, e.g., in U.S. Pat. No. 6,602,503; Sanchez-Madrid et al, (1986) Eur. J. Immunol 16: 1343-1349; Hemler et al, (1987) J Biol. Chem. 2: 11478
  • DMF Dimethyl fumarate
  • TECFIDERA® Dimethyl fumarate
  • COPAXONE® (glatiramer acetate) consists of the acetate salts of synthetic polypeptides, specifically the four naturally occurring amino acids: L-glutamic acid, L-alanine, L-tyrosine, and L-lysine (Bornstein et al. (1987) N Engl J Med. 317: 408-414). COPAXONE® exhibits structural similarity to myelin basic protein and is thought to function as an immune modulator by shifting the T helper cell type 1 response towards a T helper cell type 2 response (Duda et al. (2000) J Clin Invest 105: 967-976; Nicholas et al. (2011) Drug Design, Development, and Therapy 5: 255-274). Mitoxantrone (NOVANTRONE®, an anthracenedione molecule)
  • Mitoxantrone is an anthracenedione molecule (l,4-dihydroxy-5,8-bis[2-(2- hydroxyethylamino) ethylamino]-anthracene-9,10-dione) and a type II topoisomerase inhibitor that disrupts DNA synthesis and repair of cells. It is used to treat cancers and MS. Mitoxantrone is used to treat several forms of advancing MS, including secondary progressive MS, progressive relapsing MS, and advanced relapsing-remitting MS.
  • mitoxantrone is effective in slowing the progression of secondary progressive MS and extending the time between relapses in relapsing-remitting MS and progressive relapsing MS (Fox E (2006) Clin Ther 28 (4): 461-74).
  • Fingolimod GILENYA®; sphingosine 1-phosphate receptor modulator
  • Fingolimod is an immunomodulating drug, approved for treating MS. It has reduced the rate of relapses in relapsing-remitting multiple sclerosis by over half, but may have serious adverse effects.
  • Fingolimod is a sphingosine 1-phosphate receptor modulator, which sequesters lymphocytes in lymph nodes, preventing them from moving to the central nervous system for autoimmune responses in MS.
  • S IP Sphingosine 1-phosphate
  • Antibodies to the alpha subunit of the IL-2 receptor of T cells (daclizumab; ZEN AP AX® )
  • Daclizumab is a therapeutic humanized monoclonal antibody to the alpha subunit of the IL-2 receptor of T cells. Daclizumab was effective in reducing lesions and improving clinical scores in patients with multiple sclerosis not controlled with interferon (Rose JW et al. (2007). Neurology 69 (8): 785-789).
  • Antibody against CD 52 e.g., alemtuzumab
  • CD52 Antibodies against CD52, e.g., alemtuzumab (currently under further development as LEMTRADA®), bind to CD52, which is a protein present on the surface of mature lymphocytes, but not on stem cells.
  • LEMTRADA® high-dose subcutaneous interferon beta- la
  • RRMS relapsing - remitting MS
  • Alemtuzumab has been approved in Europe.
  • Antibody to CD20 e.g., ocrelizumab
  • Antibodies against CD20 e.g., ocrelizumab, rituximab, ofatumumab, target mature B lymphocytes.
  • Phase 2 clinical studies of rituximab and ocrelizumab in relapse remitting MS have demonstrated a statistically significant reduction in disease activity measured by brain lesions ⁇ e.g., measured by MRI scans) and relapse rate compared to placebo.
  • Inhibitors of dihydroorotate dehydrogenase e.g., teriflunomide
  • Inhibitors of dihydroorotate dehydrogenase e.g., teriflunomide
  • teriflunomide also known as A77 1726 or
  • Teriflunomide is an active metabolite of leflunomide.
  • Teriflunomide inhibits rapidly dividing cells, including activated T cells, which are thought to drive the disease process in MS.
  • Teriflunomide was investigated in clinical trials as a medication for treating MS. (Vollmer EMS News (May 28, 2009)).
  • Steroids e.g., corticosteroid, and ACTH agents can be used to treat acute relapses in relapsing -remitting MS or secondary progressive MS.
  • Such agents include, but are not limited to, DEPO-MEDROL®, SOLU-MEDROL®, DELTASONE®, DELTA-CORTEF®,
  • the method further includes the use of one or more symptom management therapies, such as antidepressants, analgesics, anti-tremor agents, among others.
  • symptom management therapies such as antidepressants, analgesics, anti-tremor agents, among others.
  • Treatment of a subject with a disease modifying IFN- ⁇ agent or non-IFN- ⁇ agent can be combined with one or more of the following therapies often used in symptom management of subjects having MS: IMURAN® (azathioprine), CYTOXAN® (cyclophosphamide), NEOSAR® (cyclophosphamide), SANDIMMUNE® (cyclosporine), methotrexate, LEUSTATIN®
  • TOPAMAX® topiramate
  • ZONEGRAN® zonisamide
  • DILANTIN® phenytoin
  • NORPRAMIN® (desipramine), ELAVIL® (amitriptyline), TOFRANIL® (imipramine), IMAVATE® (imipramine), JANIMINE® (imipramine), SINEQUAN® (doxepine), ADAPIN® (doxepine), TRIADAPIN® (doxepine), ZONALON® (doxepine), VIVACTIL® (protriptyline), MARINOL® (synthetic cannabinoids), TRENTAL® (pentoxifylline), NEUROFEN®
  • RIVOTRIL® clonazepam
  • DANTRIUM® dantrolen sodium
  • CATAPRES® clonidine
  • BOTOX® botulinum toxin
  • NEUROBLOC® botulinum toxin
  • ZANAFLEX® tizanidine
  • SIRDALUD® tizanidine
  • MYSOLINE® primidone
  • a subject identified as a non-responder will be treated with one or more agents described herein to manage symptoms.
  • Treatment refers to the administration of an IFN- ⁇ agent, alone or in combination with one or more symptom management agents, to a subject, e.g., an MS patient, to impede progression of multiple sclerosis, to induce remission, to extend the expected survival time of the subject and or reduce the need for medical interventions (e.g., hospitalizations).
  • treatment can include, but is not limited to, inhibiting or reducing one or more symptoms such as numbness, tingling, muscle weakness; reducing relapse rate, reducing size or number of sclerotic lesions; inhibiting or retarding the development of new lesions; prolonging survival, or prolonging progression-free survival, and/or enhanced quality of life.
  • the terms “prevent,” “preventing” and “prevention” contemplate an action that occurs before a subject begins to suffer from the a multiple sclerosis relapse and/or which inhibits or reduces the severity of the disease.
  • the terms “manage,” “managing” and “management” encompass preventing the progression of MS symptoms in a patient who has already suffered from the disease, and/or lengthening the time that a patient who has suffered from MS remains in remission.
  • the terms encompass modulating the threshold, development and/or duration of MS, or changing the way that a patient responds to the disease.
  • a "therapeutically effective amount" of a compound is an amount sufficient to provide a therapeutic benefit in the treatment or
  • a therapeutically effective amount of a compound means an amount of therapeutic agent, alone or in combination with other therapeutic agents, which provides a therapeutic benefit in the treatment or management of MS.
  • the term "therapeutically effective amount” can encompass an amount that improves overall therapy, reduces or avoids symptoms or causes of the disease, or enhances the therapeutic efficacy of another therapeutic agent.
  • a “prophylactically effective amount" of a compound is an amount sufficient to prevent relapse of MS, or one or more symptoms associated with the disease, or prevent its recurrence.
  • a prophylactically effective amount of a compound means an amount of the compound, alone or in combination with other therapeutic agents, which provides a prophylactic benefit in the prevention of MS relapse.
  • the term "prophylactically effective amount” can encompass an amount that improves overall prophylaxis or enhances the prophylactic efficacy of another prophylactic agent.
  • the term "patient” or “subject” refers to an animal, typically a human (i.e., a male or female of any age group, e.g., a pediatric patient (e.g., infant, child, adolescent) or adult patient (e.g., young adult, middle-aged adult or senior adult) or other mammal, such as a primate (e.g., cynomolgus monkey, rhesus monkey), that will be or has been the object of treatment, observation, and/or experiment.
  • a primate e.g., cynomolgus monkey, rhesus monkey
  • the subject has a relapsing form of MS (e.g., RRMS or relapsing SPMS).
  • the subject has RRMS and has one or more ongoing clinical exacerbations and/or subclinical activity, e.g., as shown by gadolinium (Gd) enhancement or development of new and/or enlarged T2/FLAIR lesions on magnetic resonance imaging (e.g., brain or spinal cord MRI).
  • Gd gadolinium
  • the subject has SPMS and has one or more ongoing clinical exacerbations and/or subclinical activity, e.g., as shown by gadolinium (Gd) enhancement or development of new and/or enlarged T2/FLAIR lesions on magnetic resonance imaging (e.g., brain or spinal cord MRI).
  • Gd gadolinium
  • the subject has an active form of MS, e.g., an active RRMS.
  • the MS subject has at least one newly developed lesion.
  • the MS subject has at least one pre-existing lesion.
  • the subject has RRMS, and has one or more newly developed or pre-existing lesions, or a combination thereof.
  • the subject has a baseline EDSS score of 1.5 to 7.
  • the methods described herein permit one of skill in the art to identify a monotherapy that an MS patient is most likely to respond to, thus eliminating the need for administration of multiple therapies to the patient to ensure that a therapeutic effect is observed.
  • combination treatment of an individual with MS is contemplated.
  • the IFN- ⁇ agent as described above and herein, can be administered in combination with one or more additional therapies to treat and/or reduce the symptoms of MS described herein, particularly to treat patients with moderate to severe disability (e.g., EDSS score of 5.5 or higher).
  • the pharmaceutical compositions can be administered concurrently with, prior to, or subsequent to, one or more other additional therapies or therapeutic agents. In general, each agent will be administered at a dose and/or on a time schedule determined for that agent.
  • the additional therapeutic agent utilized in this combination can be administered together in a single composition or administered separately in different compositions.
  • the particular combination to employ in a regimen will take into account compatibility of the pharmaceutical composition with the additional therapeutically active agent and/or the desired therapeutic effect to be achieved. In general, it is expected that additional therapeutic agents utilized in combination be utilized at levels that do not exceed the levels at which they are utilized individually. In some
  • the levels utilized in combination will be lower than those utilized individually.
  • Example 1 MxA as a Biomarker: MxA mRNA quantification allows the prediction of disability progression in IFNp-treated multiple sclerosis patients
  • the present example describes a 3-year prospective longitudinal study that was performed in subjects naive for treatment initiating IFNP therapy at the time of study inclusion.
  • the study permitted the analysis of IFNP bioactivity modulation in individual patients in the conditions of a real-life setting.
  • the primary outcome was the analysis of the kinetics of IFNP bioactivity loss, defined according to MxA mRNA induction, and of anti- IFNP antibody production.
  • Secondary objectives included evaluation of whether the expression of the mRNA for the IFNP receptor (IFNAR) subunits and isoforms had an impact on bioactivity loss; and correlating the markers of IFNP bioactivity with the measures of clinical disease activity, to determine whether biomarkers can predict IFNP therapy effectiveness.
  • the response to IFNP therapy was extremely heterogeneous, including patients with stable or transitory, early or late loss of IFNP bioactivity, and patients with samples lacking MxA mRNA induction in spite of absence of antibodies. No interferon receptor isoform alterations that could explain these findings were found.
  • the group level none of these biological features correlated with the measures of clinical disease activity or progression.
  • MxA mRNA was evaluated not at the single time point as a dichotomic marker (induced vs. non-induced), but as the mean of its values measured over the 6-to-24 month period, the increasing average MxA predicted a decreasing risk of short-term disability progression, independently from the presence of relapses.
  • 118 patients 36 men and 82 women, between 18 and 64 years of age, with a diagnosis of relap sing-remitting MS according to the McDonald criteria (McDonald 2001) were consecutively enrolled.
  • patients were required to have an Expanded Disability Status Scale (EDSS) ranging from 0 to 4.5, and to be naive for IFNP therapy.
  • EDSS Expanded Disability Status Scale
  • IFN bioactivity analysis was performed by real-time reverse transcriptase PCR assay that measures MxA mRNA expression in patients' whole blood samples, as previously described (Capra 2007). Accordingly, MxA mRNA induction was expressed as relative units, also called "normalization ratio" (NR), which represents the fold-change in respect to MxA mRNA expression in a standard sample of a healthy donor.
  • NR normalization ratio
  • BAb and NAb quantification were performed as previously described, using a radioimmunoprecipitation assay (RIPA) for BAbs (Capra 2007), and a cytopathic effect (CPE) inhibition assay for NAbs (Antonelli 1998).
  • RIPA radioimmunoprecipitation assay
  • CPE cytopathic effect
  • BAb analysis in order to correct for the different amount of total radioactivity obtained after each radiolabeling session, the count per minute read for each serum was normalized as the percentage of the total activity of that session; thus, the reported BAb levels are expressed as "% total activity”.
  • BAb and MxA quantification was done in all patients at all time points, exception made for MxA, which was not done at T3; NAb titer was analyzed at several time-points in selected samples (149 determinations from 84 patients).
  • the levels of Bab were expressed as count per minutes (cpm), those of Nab as ten-fold reduction units (TRU), and MxA as normalization rate (NR).
  • a first group of 63 biological responders (63%) was made up by 37 patients whose samples were MxA + , BAb-, NAb ⁇ at all time points, and by 19 individuals that had only one isolated, sporadic non-induced MxA sample, in the context of a profile of high MxA-induction and constant lack of antibodies. Of note, all of these were being treated with IFNP-la (14 with IFNP-la i.m and 5 with sc IFNP-la).
  • a second group of likely "biological responders" was made by 24 patients that were characterized, for the most part, by a conserved MxA induction, despite the presence of antibodies of the BAb class in at least four of the seven time-points analyzed, with totally absent or under-the-cut off ( ⁇ 20 TRU) NAbs.
  • MxA mRNA was induced at all time-points regardless of BAbs in 10 patients, while one MxA non-induced sample was found in 14 of them.
  • BAbs appeared as early as 3 months after therapy beginning; peaked in the subsequent time-point; and then gradually declined up to undetectable values at the end of the follow up, so that only 7 patients had BAbs at T36. Eighteen patients belonging to this group were treated with IFNP-lb.
  • a third group of 10 patients was considered biologically non-responder due to several consecutive MxA non inductions, and was further divided into two subcategories because of the heterogeneity in the seeming reasons of bioactivity loss (presence vs. absence of anti- IFNP antibodies).
  • the first subcategory was made by 8 patients whose samples resulted not only MxA-non-induced in two or more consecutive occasions, but were also simultaneously BAbs + and NAbs + ; however, NAbs, which were tested at several time-points, resulted high (>200 TRU) only in one patient and very high (>400 TRU) in another one, and in their remaining samples their level of MxA induction was just above the cut-off or stayed fairly low (4 ⁇ MxA ⁇ 16 NR). These biologically non-responders had been treated with the highest dose of IFNP (7 with IFNP-lb and 1 with IFNP-la 44 ⁇ g s.c).
  • the second subcategory of biologically non-responders was a puzzling subgroup of 2 individuals treated with IFNP-la i.m who were MxA non-induced at nearly all time-points of the follow-up, in the absence of both BAbs and NAbs. Any altered IFNAR subunit/isoform expression that could explain this seeming bioactivity loss was not found (data not shown).
  • the area bound by the realtime PCR MxA primer and probes was also sequenced, without finding any differences from the reference sequence (not shown).
  • the kinetics of bioactivity loss was peculiar in at least 4 of the 10 biological non-responders: in one patient the bioactivity loss appeared late in the course of treatment (after 30 months); in two patients treated with IFNP-lb both BAbs and NAbs disappeared and MxA reverted back to induction at T24 or at T30, suggesting that a late recovery of bioactivity is possible; also in one of the patients who had been repeatedly MxA-non-induced (but was BAb7NAb ⁇ ), MxA reverted back to induction, albeit at a low level, at T36.
  • the annualized relapse rate and the proportion of relapse-free patients after 24 or 36 months of study period were calculated and used as markers of disease activity, while an EDSS change of at least 1 -point over a period of at least two years was considered a significant marker of disability progression (Noseworthy 1990, Rudick 2010).
  • the proportion of relapse-free patients after 2 years of treatment was significantly higher among those who did not show disability progression in the same time lapse (82% vs. 20%, p ⁇ 0.001).
  • MxA + vs. MxA- a binary, dichotomic variable
  • MxA + vs. MxA- a binary, dichotomic variable
  • IFNP-non-bioactive were considered patients being MxA- and BAb-i- (and NAb+, if performed) in at least three consecutive time- points (Figure 8D).
  • Two patients were always MxA- without any antibodies.
  • Different combinations of MxA/BAb/NAb status changing over the follow up gave rise to intermediate categories.
  • IFNAR subunit/isoform modulation was not associated to decreased IFNP bioactivity, even in patients resulting MxA- without antibodies; indeed, higher amounts of soluble isoform IFNAR2.3 mRNA were associated to increased MxA mRNA levels ( Figure 9).
  • altered IFNAR subunits/isoforms expression was not found, although INFAR could have a role in determining bioactivity loss.
  • MxA was evaluated not at the single-time-point level, but as mean of the values measured over the 6-to- 24 month period, increasing MxA predicted a lower risk of 1-point-EDSS increase after 24 months (O.R.
  • IFNP bioactivity in a real-life setting was the quantification of MxA mRNA induction. Its quantification can be performed by a simple and reproducible real-time PCR assay (Pachner 2003), which can be easily transferred to the routine clinical practice (Zanotti 2010).
  • IFNP therapy and followed up clinically for 3 years, it was found that after therapy initiation MxA mRNA was stably induced to a similar extent by IFNP-la i.m., IFNP-la 44 ⁇ g s.c. and IFNP-lb preparations, with an average value that, at the group-level, does not decrease, but fluctuates only slightly over time.
  • IFNP bioactivity variations were then studied at the individual-patient level, by considering MxA expression as an all-or-nothing phenomenon and defining IFNP bioactivity as lost when MxA mRNA levels resulted below a cut-off determined in healthy subjects and MS patients naive for therapy.
  • a RIPA assay that is capable of detecting all anti-IFNP antibodies was performed.
  • a CPE assay to search for NAbs in selected samples was also performed, in order to resolve uncertain cases in which a partial or fluctuating bioactivity was observed.
  • the pattern and kinetics of antibody production was rather heterogeneous. In 8 of the 10 non bioactive patients, who were all treated with either one of the two IFNP injected subcutaneously, absence of MxA induction was always accompanied by the presence of BAbs, while NAbs were above their cut-off in the majority but not all (14 out of the 18) tested samples.
  • IFNAR modulation does not play a significant role in determining a bioactivity loss and the slight average down-modulation of the active isoform IFNAR2.2 mRNA level did not affect the average MxA induction.
  • IFNAR mRNA modulation was not correlated to IFNP bioactivity loss.
  • MxA non-induced (MxA-) may not be sensitive enough to detect small changes in disease activity or disability progression, especially on this temporal scale and relatively smaller sample size. It has to be taken into account that in some of our 10 patients classified as non-bioactive, there were sporadic samples, at certain time-points during the follow-up, in which MxA was slightly over the cut-off in presence of low/intermediate titers of NAbs, indicating that bioactivity can sometimes fluctuate between being completely lost and partially reduced but not totally absent, as if the amount of NAbs were not always sufficient to fully inhibit all IFNP binding.
  • a multivariate logistic regression model demonstrated that the proportion of the risk of 2-year progression that could be attributed to MxA was independent from the presence of clinically apparent relapses, which, by themselves, contributed as expected to this risk. More specifically, it could be estimated that patients showing an "average" value of MxA above 16 (or 4-log 2 ) relative units in the first 2 years of treatement, even in presence of clinically apparent relapses, had an estimated probability of disability progression lower than 50%, which was similar to the low probability observed in relapse-free patients. These data indicated that the levels of MxA, after being shown predictive of the relapse rate, can also be linked to a clinical measure of disability accumulation that, in turn, is predictive of long-term disability (Rio 2006, Rudick 2010). Thus, if similar results can be confirmed by larger studies, an evaluation of MxA on a quantitative scale may prove an efficient tool for identifying patients at high risk of progression, in addition to the commonly employed MRI lesion load and relapse rate.
  • MxA assay can help the clinicians to overcome the NAb dilemma.
  • the MxA mRNA assay appears as a more practical and convenient assay, easily standardized for a routine practice (Pachner 2003, Zanotti 2013); and the results in this example suggest that it is possible to set reference values indicating a higher probability of therapy success.
  • the average MxA can be considered as a reliable marker of the IFNP response long-term response, because it encompasses severity of relapses and disability, probably due to being a better marker of the in vivo IFNP effect, which is not an all-or-nothing phenomenon that the mere count of relapses can represent.
  • IFNP bioactivity profile was heterogenous in the different patients. After three years of therapy IFNP bioactivity is conserved in for most patients. BAbs alone cannot define bioactivity loss, e.g., with IFNP-lb s.c. therapy. IFNAR subunit/isoform mRNA modulation is not associated to a loss of IFNP bioactivity over time.
  • MxA mRNA quantification can stand as a primary tool to routinely monitor IFNP therapy.
  • Rudick RA Lee J-C, Simon J, Ransohoff RM, Fisher E. Defining interferonP response status in multiple sclerosis patients. Annals of Neurology. 2004 Oct;56(4):548-55. Rudick RA, Lee J, Cutter GR, et al. Disability progression in a clinical trial of relapsing- remitting multiple sclerosis: Eight-year follow-up. Arch Neurol. 2010 Nov 1 ;67 ( 11 ) : 1329—35.
  • Van der Voort LF Van der Voort LF, Vennegoor A, Visser A, Knol DL, Uitdehaag BMJ, Barkhof F, et al.
  • Spontaneous MxA mRNA level predicts relapses in patients with recently diagnosed MS.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Méthodes, dosages et trousses pour l'identification, l'évaluation et/ou le traitement d'un patient ayant la sclérose en plaques (SEP).
PCT/IB2014/002979 2013-11-01 2014-10-31 Biomarqueurs prédictifs de la réponse thérapeutique à ifnβ et utilisations de ceux-ci Ceased WO2015063604A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361899126P 2013-11-01 2013-11-01
US61/899,126 2013-11-01

Publications (2)

Publication Number Publication Date
WO2015063604A2 true WO2015063604A2 (fr) 2015-05-07
WO2015063604A3 WO2015063604A3 (fr) 2015-09-24

Family

ID=52630402

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2014/002979 Ceased WO2015063604A2 (fr) 2013-11-01 2014-10-31 Biomarqueurs prédictifs de la réponse thérapeutique à ifnβ et utilisations de ceux-ci

Country Status (1)

Country Link
WO (1) WO2015063604A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018006051A1 (fr) * 2016-07-01 2018-01-04 Dignity Health Diagnostic ou prédicteur de sclérose en plaques récurrente-rémittente

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4517288A (en) 1981-01-23 1985-05-14 American Hospital Supply Corp. Solid phase system for ligand assay
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4837168A (en) 1985-12-23 1989-06-06 Janssen Pharmaceutica N.V. Immunoassay using colorable latex particles
US4843155A (en) 1987-11-19 1989-06-27 Piotr Chomczynski Product and process for isolating RNA
US4868103A (en) 1986-02-19 1989-09-19 Enzo Biochem, Inc. Analyte detection by means of energy transfer
US5631169A (en) 1992-01-17 1997-05-20 Joseph R. Lakowicz Fluorescent energy transfer immunoassay
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US5854033A (en) 1995-11-21 1998-12-29 Yale University Rolling circle replication reporter systems
US5888507A (en) 1993-02-09 1999-03-30 Biogen, Inc. Treatment for insulin dependent diabetes
US6602503B1 (en) 1993-01-12 2003-08-05 Biogen, Inc. Recombinant anti-VLA-4 antibody molecules
WO2012109108A1 (fr) 2011-02-07 2012-08-16 Biogen Idec Ma Inc. Agents modulant s1p

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1988175A1 (fr) * 2007-05-03 2008-11-05 Bayer Schering Pharma Aktiengesellschaft Profils d'ARN prédictifs
EP2334815A4 (fr) * 2008-09-16 2012-06-20 Bayer Healthcare Llc Réponse d'interféron dans des échantillons cliniques (iris)

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4366241B1 (fr) 1980-08-07 1988-10-18
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4517288A (en) 1981-01-23 1985-05-14 American Hospital Supply Corp. Solid phase system for ligand assay
US4683202B1 (fr) 1985-03-28 1990-11-27 Cetus Corp
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4837168A (en) 1985-12-23 1989-06-06 Janssen Pharmaceutica N.V. Immunoassay using colorable latex particles
US4868103A (en) 1986-02-19 1989-09-19 Enzo Biochem, Inc. Analyte detection by means of energy transfer
US4843155A (en) 1987-11-19 1989-06-27 Piotr Chomczynski Product and process for isolating RNA
US5631169A (en) 1992-01-17 1997-05-20 Joseph R. Lakowicz Fluorescent energy transfer immunoassay
US6602503B1 (en) 1993-01-12 2003-08-05 Biogen, Inc. Recombinant anti-VLA-4 antibody molecules
US5888507A (en) 1993-02-09 1999-03-30 Biogen, Inc. Treatment for insulin dependent diabetes
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US5854033A (en) 1995-11-21 1998-12-29 Yale University Rolling circle replication reporter systems
WO2012109108A1 (fr) 2011-02-07 2012-08-16 Biogen Idec Ma Inc. Agents modulant s1p

Non-Patent Citations (85)

* Cited by examiner, † Cited by third party
Title
"Beta-interferon for multiple sclerosis", EXP CELL RES., vol. 317, no. 9, 15 May 2011 (2011-05-15), pages 1301 - 11
AEBI ET AL., MOL. CELL. BIOL., vol. 9, 1989, pages 5062 - 5072
ANTONELLI G; BAGNATO F; POZZILLI C; SIMEONI E; BASTIANELLI S; CURRENTI M ET AL.: "Development of neutralizing antibodies in patients with relapsing-remitting multiple sclerosis treated with IFN-betala", J. INTERFERON CYTOKINE RES., vol. 18, no. 5, May 1998 (1998-05-01), pages 345 - 50
ARDUINI, RM ET AL., PROTEIN EXPR PURIF, vol. 34, no. 2, 2004, pages 229 - 42
ASAI: "Methods in Cell Biology Volume 37: Antibodies in Cell Biology", vol. 37, 1993, ACADEMIC PRESS, INC.
AUSUBEL ET AL.,: "Current Protocols in Molecular Biology", 1987, JOHN WILEY & SONS
BAKER, D.P. ET AL., BIOCONJUG CHEM, vol. 17, no. 1, 2006, pages 179 - 88
BAKER, D.P. ET AL., J INTERFERON CYTOKINE RES, vol. 30, no. 10, 2010, pages 777 - 85
BARANY, PROC. NATL. ACAD. SCI. USA, vol. 88, 1991, pages 189 - 193
BELLOMI F; BRAMANTI P; TROJANO M; SCAGNOLARI C; MUTO A; SESSA E ET AL.: "Neutralizing and binding antibodies to interferon beta in patients with multiple sclerosis: a comparison of assay results from three italian centres", J IMMUNOASSAY IMMUNOCHEM, vol. 30, no. 1, 2009, pages 40 - 50
BITSCH ET AL., BRAIN, vol. 123, 2000, pages 1174 - 1183
BJARTMAR ET AL., CURR OPIN NEUROL, vol. 14, 2001, pages 271 - 278
BJARTMAR ET AL., J NEUROCYTOL, vol. 28, 1999, pages 383 - 395
BORNSTEIN ET AL., N ENGL J MED., vol. 317, 1987, pages 408 - 414
CAPRA R; SOTTINI A; CORDIOLI C; SERANA F; CHIARINI M; CAIMI L ET AL.: "IFNbeta bioavailability in multiple sclerosis patients: MxA versus antibody-detecting assays", J NEUROIMMUNOL., vol. 189, no. 1-2, September 2007 (2007-09-01), pages 102 - 10, XP022277228, DOI: doi:10.1016/j.jneuroim.2007.06.006
CHANG ET AL., N ENGL J MED, vol. 346, 2002, pages 165 - 173
CHIU AW; EHRMANTRAUT M; RICHERT ND; IKONOMIDOU VN; PELLEGRINI S; MCFARLAND HF ET AL.: "A case study on the effect of neutralizing antibodies to interferon beta 1b in multiple sclerosis patients followed for 3 years with monthly imaging", CLINICAL & EXPERIMENTAL IMMUNOLOGY, vol. 150, no. 1, 2007, pages 61 - 7
CHIU AW; RICHERT N; EHRMANTRAUT M ET AL.: "Heterogeneity in response to interferon beta in patients with multiple sclerosis: A 3-year monthly imaging study", ARCH NEUROL., vol. 66, no. 1, 1 January 2009 (2009-01-01), pages 39 - 43
COHEN JA, RUDICK RA,: "Multiple Sclerosis Therapeutics, 2nd ed.", 2003, MARTIN DUNITZ, article COHEN JA; RUDICK RA; KAPPOS L: "Interferons in relapsing remitting multiple sclerosis"
CUNNINGHAM S; GRAHAM C; HUTCHINSON M; DROOGAN A; O'ROURKE K; PATTERSON C ET AL.: "Pharmacogenomics of responsiveness to interferon IFN-0 treatment in multiple sclerosis: A genetic screen of 100 type I interferon-inducible genes", CLIN PHARMACOL THER., vol. 78, no. 6, December 2005 (2005-12-01), pages 635 - 46, XP005217604, DOI: doi:10.1016/j.clpt.2005.08.018
DUDA ET AL., J CLIN INVEST, vol. 105, 2000, pages 967 - 976
FENG X; HAN D; KILARU BK; FRANEK BS; NIEWOLD TB; REDER AT: "Inhibition of interferon-beta responses in multiple sclerosis immune cells associated with high-dose statins", ARCH NEUROL., vol. 69, no. 10, October 2012 (2012-10-01), pages 1303 - 9
FERGUSON ET AL., BRAIN, vol. 120, 1997, pages 393 - 399
FOX E, CLIN THER, vol. 28, no. 4, 2006, pages 461 - 74
FROHMAN ET AL., NEUROLOGY, vol. 61, no. 5, 2003, pages 602 - 1 1
GIACOMINI, P. S.; ARNOLD, D. L.; BAR-OR, A.; ANTEL, J. P: "Defining multiple sclerosis treatment response with magnetic resonance imaging: how much activity is too much?", ARCH. NEUROL., vol. 66, 2009, pages 19 - 20
GILLI F: "Role of differential expression of interferon receptor isoforms on the response of multiple sclerosis patients to therapy with interferon beta", J INTERFERON CYTOKINE RES., vol. 30, no. 10, October 2010 (2010-10-01), pages 733 - 41
GILLI F; MARNETTO F; CALDANO M; VALENTINO P; GRANIERI L; DI SAPIO A ET AL.: "Anti-interferon-0 neutralising activity is not entirely mediated by antibodies", JOURNAL OF NEUROIMMUNOLOGY., vol. 192, no. 1-2, December 2007 (2007-12-01), pages 198 - 205, XP022378500, DOI: doi:10.1016/j.jneuroim.2007.09.025
GILLI F; VALENTINO P; CALDANO M; GRANIERI L; CAPOBIANCO M; MALUCCHI S ET AL.: "Expression and regulation of IFNalpha/beta receptor in IFNbeta-treated patients with multiple sclerosis", NEUROLOGY, vol. 71, no. 24, 9 December 2008 (2008-12-09), pages 1940 - 7
GOODIN DS; FROHMAN EM; GARMANY GP; HALPER J; LIKOSKY WH; LUBLIN FD ET AL.: "Disease modifying therapies in multiple sclerosis: Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines", NEUROLOGY, vol. 58, no. 2, 22 January 2002 (2002-01-22), pages 169 - 78
GUATELLI ET AL., PROC. NATL. ACAD. SCI. USA, vol. 87, 1990, pages 1874 - 1878
HAGE, D.S.; TWEED, S.A., J CHROMATOGR B BIOMED SCI APPL, vol. 699, no. 1-2, 10 October 1997 (1997-10-10), pages 499 - 525
HARDY MP; OWCZAREK CM; TRAJANOVSKA S; LIU X; KOLA I; HERTZOG PJ: "The soluble murine type I interferon receptor Ifnar-2 is present in serum, is independently regulated, and has both agonistic and antagonistic properties", BLOOD, vol. 97, no. 2, 15 January 2001 (2001-01-15), pages 473 - 82
HARLOW; LANE: "Antibodies: A Laboratory Manual", 1988, COLD SPRING HARBOR LABORATORY PRESS
HARTUNG H-P; KIESEIER B; GOODIN DS; ARNASON BG; COMI G; COOK S ET AL.: "Variability in detection and quantification of interferon -l b- induced neutralizing antibodies", J NEUROINFLAMMATION., vol. 9, 2012, pages 129, XP021127211, DOI: doi:10.1186/1742-2094-9-129
HEEGAARD, N.H., J. MOL. RECOGNIT. WINTER, vol. 11, no. 1-6, 1998, pages 141 - 8
HEMLER ET AL., J BIOL. CHEM., vol. 2, 1987, pages 11478 - 11485
HEMMER B; BERTHELE A: "Should we measure the bioavailability of interferon # in vivo in patients with multiple sclerosis?", NATURE CLINICAL PRACTICE NEUROLOGY., vol. 5, no. 3, March 2009 (2009-03-01), pages 126 - 7
HESSE D; SELLEBJERG F; SORENSEN PS: "Absence of MxA induction by interferon # in patients with MS reflects complete loss of bioactivity", NEUROLOGY, vol. 73, no. 5, 4 August 2009 (2009-08-04), pages 372 - 7, XP055192052, DOI: doi:10.1212/WNL.0b013e3181b04c98
HORISBERGER ET AL., J. VIROL., vol. 64, 1990, pages 1171 - 1181
ISSEKUTZ ET AL., JLMMUNOL, vol. 147, 1991, pages 109
KILLESTEIN J; POLMAN CH: "Determinants of interferon # efficacy in patients with multiple sclerosis", NAT REV NEUROL., vol. 7, no. 4, April 2011 (2011-04-01), pages 221 - 8, XP055212231, DOI: doi:10.1038/nrneurol.2011.22
KOMEK ET AL., AM J PATHOL, vol. 157, 2000, pages 267 - 276
KU ET AL., IMMUNOL. CELL BIOL., vol. 89, 2011, pages 173 - 182
KURTZKE, ANN. NEUROL., vol. 36, 1994, pages 573 - 79
KURTZKE, NEUROLOGY, vol. 33, 1983, pages 1444
KWOH ET AL., PROC. NATL. ACAD. SCI. USA, vol. 86, 1989, pages 1173 - 1177
LEE ET AL., INT MS JOURNAL, vol. 15, 2008, pages 12 - 18
LIZARDI ET AL., BIOLTECHNOLOGY, vol. 6, 1988, pages 1197
MALUCCHI S; GILLI F; CALDANO M; MARNETTO F; VALENTINO P; GRANIERI L ET AL.: "Predictive markers for response to interferon therapy in patients with multiple sclerosis", NEUROLOGY, vol. 70, no. 13, 25 March 2008 (2008-03-25), pages 1119 - 27, XP055212165, DOI: doi:10.1212/01.wnl.0000304040.29080.7b
MALUCCHI S; GILLI F; CALDANO M; SALA A; CAPOBIANCO M; SAPIO A ET AL.: "One-year evaluation of factors affecting the biological activity of interferon beta in multiple sclerosis patients", JOURNAL OF NEUROLOGY, vol. 258, no. 5, 12 December 2010 (2010-12-12), pages 895 - 903, XP019900519, DOI: doi:10.1007/s00415-010-5844-5
MCDONALD ET AL., ANN. NEUROL., vol. 36, 1994, pages 14
MCDONALD ET AL.: "Recomended diagnostic criteria for Multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis", ANN NEUROL, vol. 50, 2001, pages 121 - 127
MCDONALD WI; COMPSTON A; EDAN G; GOODKIN D; HARTUNG H-P; LUBLIN FD ET AL.: "Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis", ANNALS OF NEUROLOGY, vol. 50, no. 1, 2001, pages 121 - 7
MENZIN J; CAON C; NICHOLS C; WHITE LA; FRIEDMAN M; PILL MW: "Narrative review of the literature on adherence to disease-modifying therapies among patients with multiple sclerosis", JOURNAL OF MANAGED CARE PHARMACY: JMCP, vol. 19, no. 1, 2013, pages 524 - 40
NICHOLAS ET AL., DRUG DESIGN, DEVELOPMENT, AND THERAPY, vol. 5, 2011, pages 255 - 274
NOSEWORTHY JH; VANDERVOORT MK; WONG CJ; EBERS GC: "Neurology", vol. 40, June 1990, THE CANADIAN COOPERATION MS STUDY GROUP, article "Interrater variability with the Expanded Disability Status Scale (EDSS) and Functional Systems (FS) in a multiple sclerosis clinical trial", pages: 971 - 5
OLIVER B; MAYORGA C; FERNÁNDEZ V; LEYVA L; LE6N A; LUQUE G ET AL.: "Interferon receptor expression in multiple sclerosis patients", J. NEUROIMMUNOL., vol. 183, no. 2, February 2007 (2007-02-01), pages 225 - 31, XP022497030, DOI: doi:10.1016/j.jneuroim.2006.11.010
PACHNER A; NARAYAN K; PRICE N; HURD M; DAIL D: "MxA gene expression analysis as an interferon-beta bioactivity measurement in patients with multiple sclerosis and the identification of antibody-mediated decreased bioactivity", MOL DIAGN, vol. 7, no. 1, 2003, pages 17 - 25
PATY ET AL., NEUROLOGY, vol. 43, 1993, pages 665
PEPINSKY, RB ET AL., J. PHARMACOL. EXP. THER., vol. 297, no. 3, 2001, pages 1059 - 66
PETERSON ET AL., J NEUROPATHOL EXP NEUROL, vol. 61, 2002, pages 539 - 546
POLMAN CH; BERTOLOTTO A; DEISENHAMMER F; GIOVANNONI G; HARTUNG H-P; HEMMER B ET AL.: "Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis", THE LANCET NEUROLOGY., vol. 9, no. 7, July 2010 (2010-07-01), pages 740 - 50, XP027598949, DOI: doi:10.1016/S1474-4422(10)70103-4
PULIDO ET AL., J BIOL. CHEM., vol. 266, 1991, pages 10241 - 10245
RIO J; NOS C; TINTORE M; TELLEZ N; GALAN I; PELAYO R ET AL.: "Defining the response to interferon-0 in relapsing-remitting multiple sclerosis patients", ANNALS OF NEUROLOGY, vol. 59, no. 2, 2006, pages 344 - 52
RIO, J.; COMABELLA, M.; MONTALBAN, X.: "Predicting responders to therapies for multiple sclerosis", NAT. REV. NEUROL., vol. 5, 2009, pages 553 - 560
RIVAS, G.; MINTON, A.P., TRENDS BIOCHEM SCI., vol. 18, no. 8, 1993, pages 284 - 7
ROSE JW ET AL., NEUROLOGY, vol. 69, no. 8, 2007, pages 785 - 789
RUDICK RA; LEE J; CUTTER GR ET AL.: "Disability progression in a clinical trial of relapsing-remitting multiple sclerosis: Eight-year follow-up", ARCH NEUROL., vol. 67, no. 11, 1 November 2010 (2010-11-01), pages 1329 - 35
RUDICK RA; LEE J-C; SIMON J; RANSOHOFF RM; FISHER E: "Defining interferonØ response status in multiple sclerosis patients", ANNALS OF NEUROLOGY., vol. 56, no. 4, October 2004 (2004-10-01), pages 548 - 55
S RENSEN PS; DEISENHAMMER F; DUDA P; HOHLFELD R; MYHR K-M; PALACE J ET AL.: "Guidelines on use of anti-IFN-(3 antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-0 antibodies in multiple sclerosis", EUROPEAN JOURNAL OF NEUROLOGY, vol. 12, no. 11, 2005, pages 817 - 27, XP002435172, DOI: doi:10.1111/j.1468-1331.2005.01386.x
SAMBROOK ET AL.,: "Molecular Cloning: A Laboratory Manual, 2nd ed.,", 1989, COLD SPRING HARBOR LABORATORY PRESS
SANCHEZ-MADRID ET AL., EUR. J. IMMUNOL, vol. 16, 1986, pages 1343 - 1349
SERANA F; SOTTINI A; GHIDINI C; ZANOTTI C; CAPRA R; CORDIOLI C ET AL.: "Modulation of IFNAR1 mRNA expression in multiple sclerosis patients", J. NEUROIMMUNOL., vol. 197, no. 1, 15 June 2008 (2008-06-15), pages 54 - 62, XP023314441, DOI: doi:10.1016/j.jneuroim.2008.03.019
SIPE ET AL., NEUROLOGY, vol. 34, 1984, pages 1368
SJOLANDER, S.; URBANICZKY, C., ANAL. CHEM., vol. 63, 1991, pages 2338 - 2345
SORMANI MP; BONZANO L; ROCCATAGLIATA L; CUTTER GR; MANCARDI GL; BRUZZI P: "Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: A meta-analytic approach", ANNALS OF NEUROLOGY, vol. 65, no. 3, 2009, pages 268 - 75
STITES; TERR: "Basic and Clinical Immunology 7th Edition", 1991
SZABO ET AL., CURR. OPIN. STRUCT. BIOL., vol. 5, 1995, pages 699 - 705
TRAPP ET AL., N ENGL JMED, vol. 338, 1998, pages 278 - 285
VAN DER VOORT LF; VENNEGOOR A; VISSER A; KNOL DL; UITDEHAAG BMJ; BARKHOF F ET AL.: "Spontaneous MxA mRNA level predicts relapses in patients with recently diagnosed MS", NEUROLOGY, vol. 75, no. 14, 2010, pages 1228 - 33
VITALE G; HERDER WW DE; KOETSVELD PM VAN; WAAIJERS M; SCHOORDIJK W; CROZE E ET AL.: "IFN-0 Is a Highly Potent Inhibitor of Gastroenteropancreatic Neuroendocrine Tumor Cell Growth In vitro", CANCER RES., vol. 66, no. 1, 1 January 2006 (2006-01-01), pages 554 - 62
VOLLMER, EMS NEWS, 28 May 2009 (2009-05-28)
WEITZ ET AL., J. INTERFERON RES., vol. 9, 1989, pages 679 - 689
ZANOTTI C; GHIDINI C; LAMORGESE C; CAIMI L; CAPRA R; IMBERTI L: "Transfer of myxovirus-protein-A mRNA assay for interferon-0 bioactivity measurement in multiple sclerosis patients to routine laboratory practice. A 4-year experience", CLINICAL CHEMISTRY AND LABORATORY MEDICINE, vol. 48, no. 9, 2010, pages 1235 - 8

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018006051A1 (fr) * 2016-07-01 2018-01-04 Dignity Health Diagnostic ou prédicteur de sclérose en plaques récurrente-rémittente
CN109562280A (zh) * 2016-07-01 2019-04-02 尊严健康公司 复发-缓解型多发性硬化的诊断或预测因子
US11774460B2 (en) 2016-07-01 2023-10-03 Dignity Health Diagnostic or predictor of relapsing remitting multiple sclerosis
IL264044B1 (en) * 2016-07-01 2025-01-01 Dignity Health Diagnoses or predicts progression to multiple sclerosis of the focal paroxysmal type
US12253531B2 (en) 2016-07-01 2025-03-18 Dignity Health Diagnostic or predictor of relapsing remitting multiple sclerosis
IL264044B2 (en) * 2016-07-01 2025-05-01 Dignity Health Diagnostic or predictor of relapsing remitting multiple sclerosis
EP4521117A3 (fr) * 2016-07-01 2025-06-04 Dignity Health Diagnostic ou prédicteur de sclérose en plaques récurrente-rémittente

Also Published As

Publication number Publication date
WO2015063604A3 (fr) 2015-09-24

Similar Documents

Publication Publication Date Title
US20160045570A1 (en) Biomarkers predictive of therapeutic responsiveness to ifnb and uses thereof
Assis et al. The role of macrophage migration inhibitory factor in autoimmune liver disease
EP3183582B1 (fr) Biomarqueurs pour le diagnostic et le suivi de maladies neuro-immunologiques
AU2009275110B2 (en) Novel oncogene NRF2
WO2017196432A1 (fr) Compositions et méthodes de diagnostic et de traitement d'une maladie neurodégénérative
ES2818823T3 (es) Método de evaluación del riesgo de LMP
JP2018535394A (ja) Ｉｌ２３経路バイオマーカーを使用するｉｌ２３アンタゴニストに対する臨床応答の予測
TW201307845A (zh) 預測方法及利用ｉｌ－１７拮抗劑治療關節炎的方法
KR20150010709A (ko) Il-17 길항제를 사용하는 강직성 척추염의 치료 방법
US20230236188A1 (en) Methods of diagnosing and treating lupus
US8293468B2 (en) MCAM modulation and uses thereof
Hegen et al. Predictors of response to multiple sclerosis therapeutics in individual patients
CN107076757A (zh) 基于RGMa片段的诊断测定
WO2012071436A1 (fr) Procédé de traitement de maladies inflammatoires autoimmunes utilisant des mutants perte de fonction il-23r
US20100284933A1 (en) Biomarkers of Multiple Sclerosis
US20160368992A1 (en) A method of increasing gipcr signalization in the cells of a scoliotic subject
WO2017176385A1 (fr) Compositions et méthodes de diagnostic et de traitement d'une lésion cérébrale
WO2015063604A2 (fr) Biomarqueurs prédictifs de la réponse thérapeutique à ifnβ et utilisations de ceux-ci
WO2024182718A2 (fr) Compositions et procédés associés à des auto-anticorps du récepteur de la transcobalamine
KR20160020553A (ko) 특발성 척추측만증의 심각한 진행에 대한 새로운 마커, 그리고 척추측만 환자를 층화하고 척추측만증이 발달할 위험을 예측하기 위한 이들의 용도
JP2020525019A (ja) 白血病におけるｃｔｌａ４アンタゴニストに対する耐性を同定および治療するための組成物および方法
US20180313830A1 (en) Peptide and biomarker associated with inflammatory disorders, and uses thereof
Farrell Neutralising antibodies to interferon beta in multiple sclerosis
US20250354998A1 (en) Methods of diagnosing and treating multiple sclerosis by detecting a biomarker in the cerebrospinal fluid
CA2774286A1 (fr) Utilisation de populations de cellules nk immunoregulatrices pour predire l'efficacite d'anticorps anti-il-2r dans des patients atteints de sclerose en plaques

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14843179

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14843179

Country of ref document: EP

Kind code of ref document: A2